Reports ranked by overall diligence score. Newer reports break ties, so the list stays stable as fresh research lands.
The three highest-scoring diligence reports in the collection.
Commure is the breadth-and-anchor leader in healthcare AI, and the BUY case rests on KLAS, OBHG, HCA, and the GC Customer Value Fund composing the strongest public proof book in the category.
NetSPI is the dominant pure-play proactive security platform at scale, with $500M+ KKR backing, consistent 30–50%+ organic revenue growth through 2023, and an unmatched combination of elite human expertise and AI—making it a compelling strategic asset in the expanding CTEM market.
Hinge Health is the AI-native category leader in digital MSK care, delivering industry-leading revenue growth (+47% YoY), an 85% gross margin, and positive free cash flow as a public company—making it a strong buy for investors with a 3–5 year horizon, with a primary watch item on the FDA TrueMotion inquiry.
Remaining reports by score.
Stripe is a premium-quality private fintech compounder, but the current tender price still needs more audited support than public evidence can provide.
Enter is the dominant AI-powered mass-litigation platform for Brazil's uniquely vast legal market, growing at exceptional speed with blue-chip customers and Tier-1 investors, but carrying key-person and market-concentration risk as it attempts global expansion.
Temporal has achieved rare developer infrastructure category leadership with 183,000+ weekly active OSS users and 2,500+ cloud customers, a 184% NRR confirming durable enterprise expansion, and 380% YoY revenue growth in early 2026. The company is well-positioned to benefit from the AI agent orchestration wave through Nexus. The primary investment question is whether the OSS-to-cloud conversion flywheel can sustain growth as the platform matures and hyperscalers develop competing native orchestration services.
TRM Labs' 150%+ annual growth and rare dual presence in both private-sector compliance and government investigations makes it one of the most defensible blockchain intelligence platforms, but Chainalysis's entrenched position and market cyclicality warrant careful sizing.
EquipmentShare is a Buy at IPO — a vertically integrated construction tech + rental platform trading at a substantial discount to large-cap rental peers, with 34%+ rental growth, a capital-light OWN Program, and an undervalued T3 SaaS layer.
Canva is a world-class design platform — profitable, growing 35%+, and an efficient consumer-to-enterprise flywheel. At 12.7x ARR ($42B), the valuation is fair for the growth/profitability profile but offers limited margin of safety; BUY with medium-high confidence for investors with a 2-4 year institutional horizon.
Fal is the leading infrastructure layer for generative media inference, with extraordinary revenue growth, a clear developer moat, and a $4.5B valuation backed by top-tier investors — but faces intense competition and unverified financial disclosures.
Gusto is a buy at $9.3B: $1B+ actual revenue, FCF-positive, accelerating growth, and a 9x multiple that is materially discounted vs. Rippling and Deel—positioning it for significant IPO upside when markets reopen.
Insider is a scaled global martech platform with credible product breadth and customer adoption, but limited public financial disclosure and a rich late-stage price reference argue for disciplined tracking rather than aggressive underwriting.
Applied Intuition is the dominant private platform for autonomous vehicle development infrastructure, with deep OEM penetration and a growing defense franchise; its $15B valuation is stretched on available evidence but defensible if undisclosed revenue confirms the claimed profitability and triple-digit growth trajectory.
Nozomi Networks is the global OT/CPS security market leader with 12,000+ deployments and $100M+ ARR, now operating as a Mitsubishi Electric subsidiary with an estimated EV of $1.4B–$1.8B at 9–11x ARR; recommend Track pending disclosure of deal economics and integration trajectory.
NinjaOne is the category leader in MSP RMM with 70% revenue growth, 35,000+ customers, and a verified G2 #1 position — but the $5B entry valuation is priced for continued high growth and requires blocking diligence (audited financials, NRR, SOC 2) before capital commitment.
Tines is a fast-growing, profitable-architecture workflow automation unicorn with strong ARR growth, deep customer relationships, and an expanding AI product surface — attractive at current momentum but priced for continued hyper-growth.
Hugging Face is the clear network-effect leader in open-source AI infrastructure with dominant platform position, strong ARR growth, and strategic investor alignment — but faces structural monetization risk from its free-tier model and unverified profitability.
Wiz is the fastest-growing enterprise security company ever built — $500M+ ARR in under 5 years, 40-45% Fortune 100 penetration, and a genuinely differentiated Security Graph architecture. At $32B (~64x ARR), the valuation reflects extraordinary expectations. The base-case IPO outcome is $17-25B (25-45% below the last private round). The bull case ($28-32B at IPO) requires sustained 38%+ ARR growth and public market multiple re-rating that current conditions do not support. Wiz is a conditional long: diligence- worthy, but entry at $32B requires explicit conviction in the bull case and a 3-5 year hold horizon.
Abnormal Security is the clearest AI-native disruption story in enterprise email security, with 100% ARR growth, 2,800+ enterprise customers, and a Gartner Magic Quadrant Vision leadership position validated by independent analysts. The $5.1 billion Series D valuation at ~25× ARR is steep relative to public cybersecurity peers (11–15× ARR), but is defensible if the company sustains 70%+ ARR growth through its targeted Q4 2025 IPO. The primary risks are Microsoft Defender's zero-marginal-cost bundling threat and multiple compression if growth decelerates. A **Conditional Buy** for sophisticated investors who can obtain NDR and margin disclosures in due diligence.
Databricks is a premier late-stage data-and-AI platform, but the current $134B price still looks stretched versus public comps and available disclosure.
Abridge has achieved best-in-class product-market fit in the fastest-growing segment of healthcare AI, backed by top-tier investors and a unique Epic distribution moat. The $5.3B Series E valuation prices in aggressive growth and market expansion that is not yet evident in confirmed revenue. Patient consent litigation and Epic's own AI roadmap are material risks. A compelling hold for existing investors; new investors should require revenue transparency before committing at current valuation.
Vi Labs is a qualified BUY as a leading enterprise AI platform for healthcare data intelligence, supported by a $1.64B valuation, a 190M-record data moat, and 100+ enterprise customers, tempered by undisclosed financials.
Octane is a profitable, high-growth specialty fintech lender with a defensible moat in powersports and recreational markets; the $1.3B valuation is fair given GAAP profitability and 29% originations growth, making this a buy for specialty fintech investors with medium confidence pending full financial disclosure.
Gamma is the most capital-efficient path to $100M ARR in AI SaaS and warrants a conditional buy at a 15–20% discount to the Series B price, subject to private diligence confirming net dollar retention, gross margin, and enterprise revenue durability.
Nominal's 7x revenue growth and four-of-five-largest-defense-contractor deployment prove real product-market fit in a structurally underserved niche, but undisclosed absolute revenue and gross margin prevent a buy call at a $1 billion valuation that requires roughly $60–90 million of ARR to be supportable.
ICEYE is one of the strongest private space companies on public evidence, but the current price already assumes sovereign-contract execution and margin durability that outside investors still cannot fully verify.
Supabase has real platform traction and product depth, but limited public disclosure tempers conviction at a $2B valuation.
Nerdio is the category-leading Microsoft EUC management platform with $100M+ ARR, 85%+ growth, profitable operations, and unicorn status, but is subject to existential single-vendor risk from Microsoft and financial opacity that limits investment-grade due diligence.
Lambda Labs is the most credible independent GPU cloud challenger — NVIDIA equity alignment, 10k+ customers, and hyperscaler validation earn a conditional BUY at Series E terms, subject to ARR confirmation and CEO transition monitoring.
Anyscale is a strong buy for infrastructure-focused investors: it owns the dominant open-source distributed ML framework (Ray), has a credible enterprise commercial layer, and is well-positioned to capture the fast-growing AI infrastructure market — but open-source self-hosting risk and hyperscaler competition constrain revenue multiples.
Cribl is the dominant independent telemetry pipeline vendor with $300M+ ARR, 9,000+ enterprise deployments, and a five-product platform that makes switching costs substantial and churn unlikely—a compelling late-stage buy at current $3.5B valuation.
Fleetio is a category-defining fleet maintenance SaaS platform with a durable maintenance-first moat reinforced by the Auto Integrate shop network; the $1.5B+ valuation appears reasonable at 10–15x estimated ARR, but sustained growth execution and competitive resilience against telematics bundling are the key de-risking factors for investment.
Vanta is the leading GRC automation platform with $300M+ ARR, 63% YoY growth, and a defensible integration moat — a Conditional Buy at ~14× ARR contingent on NRR and margin confirmation.
Armis is a Gartner MQ Leader in CPS protection with 35+ Fortune 100 customers, $300M+ ARR, and 50%+ YoY growth; acquired by ServiceNow at 23x ARR — a fair price for a high-growth platform leader facing integration and OT depth risks.
ElevenLabs is the category-defining AI voice infrastructure company: 175% ARR growth, elite investor syndicate, and a defensible quality moat — but Series D entry at 33× ARR compresses new investor returns and requires the platform thesis to beat BigTech bundling.
Legora has category-leading growth in legal AI, but the current valuation already prices in a large share of the upside.
Kailera is one of the best-capitalized public obesity biotechs and already has unusually strong precommercial efficacy positioning, but public investors still need global Phase 3 confirmation before the valuation case graduates from a catalyst-driven track posture to a clear buy.
Govini looks investable because it has crossed meaningful ARR scale and built a real DoD software moat, but conviction is capped by sparse disclosure on retention, concentration, and unit economics.
Cognite shows real industrial-AI traction and top-tier customer proof, but opaque private-market pricing and incomplete financial disclosure justify a TRACK recommendation rather than an immediate buy.
Illumio is the undisputed microsegmentation leader with 1,000+ enterprise customers, a 12-year technical head-start over Big-4 platform rivals, and powerful regulatory tailwinds from DORA and CISA zero-trust mandates — but private financial opacity, long sales cycles, and Big-4 platform consolidation risk make this a monitored conviction-buy, not a slam dunk.
Nuvemshop is the dominant LatAm e-commerce infrastructure play with a strong moat, but a compressed valuation environment and execution risk on financial services expansion warrant a cautious buy at fair pricing.
CFS is the highest-quality, most credibly funded private fusion company globally, with the world's most advanced Q>1-targeting tokamak (SPARC), the first signed corporate fusion PPAs (Google + Eni), and a $3.2B investor base led by Breakthrough Energy Ventures, Khosla, and Eni. SPARC first plasma (2026) and Q>1 (2027) are the next binary milestones that determine whether CFS can close the $3–5B ARC construction capital gap. At an estimated $5–8B valuation, the market prices a ~65% SPARC Q>1 probability; the primary underpriced risk is tritium breeding (TRL 2–3 globally), which could delay ARC commercial operations regardless of SPARC success. Constructive on a 6–10 year horizon for deep-tech energy transition funds.
Exotec is Europe's most differentiated warehouse robotics vendor with a defensible 3D AMR moat and a $400M Next-Gen backlog — conditional positive at base-case pricing, subject to four pre-investment diligence conditions.
ClickHouse has strong product-market pull, credible cloud monetization, and marquee customer adoption, but its private-market valuation already prices in substantial future execution despite limited public disclosure on revenue quality and margins.
Tailscale looks like a strong, technically differentiated secure-networking company with real customer love and credible category expansion, but the April 2025 Series C valuation remains hard to underwrite cleanly without public ARR, margin, and retention disclosure.
Outstanding enterprise AI platform with real revenue and traction; $7.2B valuation at 36x ARR provides insufficient margin of safety given hyperscaler bundling risk and undisclosed NRR.
Harmonic is the leading formal-mathematics AI company, holding benchmark records at the IMO and VERINA level, but faces unproven monetization and a concentrated key-person risk from Vlad Tenev's concurrent Robinhood CEO role.
Cast AI delivers measurable cloud savings and AI-infrastructure optionality, but undisclosed revenue and round economics keep the unicorn valuation from looking clearly underwritten.
TerraPower is one of the most credible US advanced-nuclear commercialization stories approaching market entry, but public-only evidence still cannot support a clean underwriting call because valuation, economics, and fuel-chain details remain opaque.
Aven has created a genuinely differentiated fintech product—the home-equity-backed credit card—with strong early traction, but execution risk around the CCB bank dependency, FCRA litigation, and the untested 'machine banking' roadmap warrants a careful track rating ahead of any Series F or IPO.
Securiti AI achieved a strong strategic exit at $1.725B — validating its unified data platform thesis — but revenue opacity and post-acquisition integration execution remain the key unresolved questions.
Unitree is one of the few humanoid and legged-robot companies with visible product pricing, real revenue signals, and apparent scale, but policy risk and disclosure gaps justify a disciplined track stance rather than an aggressive buy.
Fictiv is a strategically valuable but still financially opaque digital manufacturing platform: MISUMI's $350M acquisition looks fair against the disclosed 2024 revenue base and public comp ranges, but independent underwriting remains constrained by limited private-company disclosure.
Dream Games is a CONDITIONAL BUY — Royal Match is one of the most capital-efficient mobile games ever built, but single-game revenue concentration, a stale 2022 valuation, and mounting gambling-regulation risk require heavy diligence before committing capital.
Horizon3.ai is the autonomous pentesting category leader with a FedRAMP-validated federal moat, 5,200+ customers, and 102% ARR growth—but its ~$1B unicorn valuation at undisclosed absolute ARR implies a premium multiple that warrants further diligence on revenue scale and customer concentration before conviction investing.
ElevateBio is a differentiated advanced therapy CDMO with a proprietary gene editing platform, $1.25B in total funding, and a strategic Novo Nordisk partnership, but faces meaningful execution risk from a January 2026 CEO transition and a 13% post-Series-D workforce reduction.
ReliaQuest is a well-capitalized late-stage cybersecurity leader with a compelling vendor-neutral Open XDR platform and strong enterprise traction, but faces intensifying competition from platform consolidators (Microsoft, Palo Alto, CrowdStrike) and carries meaningful risk from its undisclosed unit economics and key-person dependence on founder Brian Murphy.
Augury is a category-leading industrial AI company with strong customer proof points and a growing dataset moat, but its $1B+ valuation faces pressure from an incomplete financial picture and intensifying competition from well-resourced incumbents.
Solugen offers a compelling technology platform for sustainable industrial chemicals but faces significant scale-up execution risk as it ramps Bioforge Marshall.
Arctic Wolf is the leading pure-play MDR/SOC-as-a-Service provider with strong ARR growth and a broad platform, but faces valuation compression risk and integration execution challenges after rapid M&A.
Deel's owned-entity moat and $1B ARR at 75% growth justify a conditional buy at $17.3B — but audited margins and RICO litigation reserves are pre-commitment break conditions.
Hadrian is executing the right industrial thesis with credible defense customers and extraordinary growth, but the $1.6 B valuation at over 50x TTM revenue demands Factory 4 delivery and structural transparency before a high-conviction position is justified.
Dexterity has the most commercially validated physical AI platform in warehouse logistics, but the $1.65 B entry price at ~25× ARR requires a near-term Series D to sustain the capital-intensive RaaS deployment model.
Kiteworks is the compliance-grade private content network leader: profitable, growing at $130M+ ARR, with a defensible FedRAMP moat — but Accellion's breach legacy and an unaudited financial profile require disciplined diligence.
ThreatLocker is a high-growth unicorn with a differentiated default-deny Zero Trust approach and strong MSP channel traction, but faces revenue transparency gaps and increasing competition from well-funded incumbents.
Porter has established dominant market leadership in India's intra-city logistics segment, reached unicorn status in 2025 with strong revenue growth and first-ever profitability, but faces structural gig-economy regulatory risk and an unclear IPO timeline.
Twelve has the right technology, team, and customers to become the defining PtL-SAF company—but the entire thesis hinges on AirPlant One's commercial performance, which remains unproven.
Altana holds a defensible government-validated moat in supply chain AI compliance with a proprietary data flywheel and no direct certified competitor, but private financials and professional services complexity require data room validation before committing.
Notion is the AI workspace category leader with 100M+ users, $500M+ ARR, and accelerating AI monetization — but trades at a stretched 22x ARR multiple vs. public comps, with key unit economics (NRR, gross margin) undisclosed.
Flo Health is the dominant consumer femtech app globally with a defensible data moat, strong MAU growth, and confirmed positive cash flow, but opaque financials, ongoing privacy litigation, and Apple's native competition constrain the risk-adjusted upside at $1B+ valuation.
Saronic is the leading pure-play autonomous naval vessel startup with strong Navy traction, but its premium valuation and single-customer concentration warrant careful monitoring.
Runway is the best-positioned independent generative video AI company, with strong revenue momentum, a differentiated product roadmap anchored by GWM-1, and deep enterprise partnerships — but faces meaningful legal, competitive, and profitability risks that stretch its $5.3B valuation.
Agility Robotics has achieved what no other humanoid robot company has: a proven, production-grade commercial deployment at scale. With 100,000+ totes moved at GXO Logistics, a $641M funding base, and a dedicated manufacturing facility targeting 10,000 units per year, Agility holds a 12–24 month commercialization lead over the field. The central investment question is whether it can convert this first-mover advantage into durable market position before better-funded competitors (Figure AI at $39B valuation, Tesla Optimus with manufacturing scale) close the deployment gap. Unit economics are unproven at scale, customer concentration is a real risk, and cooperative safety certification remains the gating technology for broader adoption.
MENA's most valuable fintech and dual-year profitable BNPL leader enters IPO runway at a stretched $3.3-4.5B valuation; dominant KSA positioning and wallet expansion support a Track rating pending audited IPO financials.
Vercel is the dominant Frontend Cloud with genuine competitive moats through Next.js stewardship and the AI deployment flywheel. At $9.3B (27x ARR), the valuation is fair on a growth-adjusted basis but thin on margin of safety — CONDITIONAL PASS pending NRR and gross margin disclosure.
KLAS #1 Healthcare AI Platform at Reasonable Forward Multiple — Conditional Positive Subject to ARR and Gross Margin Diligence
Monzo is the UK's first profitable digital bank at scale — fair entry at $5.9B with 2–3× MOIC if IPO re-rating occurs; track with conviction pending FY2026 revenue print.
Cursor is the fastest-growing developer SaaS in history at $2B ARR, with category- defining AI coding leadership and 64-70% Fortune 500 penetration (company-claimed). At $29.3B valuation (14.7x ARR), the entry is defensible against high-growth public comps but priced for gross margin improvement that has not yet materialized. The SpaceX $60B acquisition option caps near-term returns at ~2x; investors must secure governance rights to the acquisition decision and confirm gross margin improvement trajectory before this investment clears a 3x+ return threshold. Recommendation: SELECTIVE BUY (conditional).
Synthesia is the enterprise AI video market leader — a conditional investment at $4.0B. The company's top-decile metrics (142% NRR, 66% ARR growth, 77%+ gross margin, 70%+ Fortune 100 penetration) justify a premium revenue multiple, but the 27x trailing ARR valuation leaves little margin for execution error. Key risks — EU AI Act compliance gap, undisclosed GRR, and Microsoft/Google AI video bundling — require diligence completion before commitment. CONDITIONAL PROCEED for high risk-tolerance investors with AI regulatory expertise. HolonIQ added Synthesia to its EdTech unicorn list in December 2025 at $4.0B, validating enterprise L&D adoption quality.
TRACK: Uzum has credible national scale, ecosystem breadth, and reported profitability, but the current $2.3 billion reference point looks fair-to-stretched for new common equity until valuation terms and segment economics are cleaner.
Baseten is a high-quality AI inference infrastructure company with real enterprise traction and strong category positioning, but public financial disclosure is too thin to justify treating momentum pricing as a high-conviction buy.
MaintainX is a strong vertical SaaS operator in industrial maintenance, but the $2.5B Series D mark looks stretched without audited revenue, NRR, or margin disclosure.
Nourish has built a scaled, payer-aligned virtual metabolic-care platform with strong clinical and distribution signals, but the reported $1.75 billion 2026 valuation looks stretched until management discloses revenue, margins, and reimbursement durability in more detail.
Alan has built the strongest full-stack digital health-insurance franchise in France, but unresolved underwriting opacity, cyber dependency, and public-sector concentration keep the current €5B valuation in watchlist rather than buy territory.
Mollie is a profitable, fast-growing European payments platform with a credible SME leadership position, but its €5.4B Series C mark faces post-2021 multiple compression and a meaningful GoCardless integration execution risk.
Netskope is a best-in-class SSE/SASE platform with 116% NRR and 32% revenue growth, but trades at a 50% discount to cloud-security peers post-IPO, warranting a track/cautious-buy stance pending competitive clarification from Microsoft Entra SSE.
Coalition is the most differentiated technology-enabled cyber insurer in the US market, but complete financial opacity and the unpriced risk of systemic tail events mean a conditional proceed — not a buy — until the data room confirms the financial thesis.
Crusoe is the most credibly positioned vertically integrated AI factory company with a proven energy-first thesis, 2.1 GW committed campus, $10B+ valuation, and NVIDIA preferred-partner status — but faces GPU pricing commoditization, acute customer concentration, an unexplained March 2025 outage, and an ESG contradiction from the Engine No. 1 natural gas JV that could impair enterprise sales.
Track Quantum Systems with price discipline: customer and product proof are strong, but private financials and regulatory/Ukraine exposure keep underwriting confidence at medium.
Moniepoint is Nigeria's dominant SME payment and banking infrastructure — 14B transactions, $294B TPV, 6M+ businesses — at a $1B valuation that implies ~1.7x revenue (compressed vs peers), but active CBN enforcement, NPL opacity, and no audited financials demand disciplined open-book underwriting before any new capital commitment above $2B pre-money.
Spring Health is the best-evidenced employer mental health unicorn globally, with a JAMA 2025 peer-reviewed RCT providing gold-standard clinical outcomes proof unavailable from any direct competitor. The $3.3B Series E valuation (April 2024) is the highest for an independent employer mental health benefits company and implies 11–25× ARR at a wide analyst estimate range ($130–300M). The investment thesis is a conditional buy: strong clinical proof, MHPAEA enforcement tailwind, and Alma-enabled multi-channel optionality support a premium valuation, but financial opacity (zero ARR disclosure), MHPAEA NQTL compliance risk, and unquantified Guide AI clinical liability create material conviction gaps that require data room access before term sheet. For growth-stage investors with a 4–7 year horizon.
Island has category leadership and a financial services moat, but the $4.85B Series E prices in near-perfect execution — NDA diligence on NRR and burn is required before any investment.
Carrier Network Moat and 30%+ Growth Earn Conditional Buy at Secondary Discount — NRR and Gross Margin Disclosure Required Before Full Commitment
Revolut's banking licence, $4B revenue, and $1.4B profit justify a CONDITIONAL BUY at $75B; regulatory execution risk and crypto revenue cyclicality bound the margin of safety.
Rippling looks like one of the strongest compound-software companies in workforce operations, but public evidence is still too thin to endorse the $16.8B mark with confidence.
Modal has earned a track call by demonstrating $300M ARR with 5x growth in seven months, a diversified high-quality customer roster, and a technically differentiated serverless platform with Sandbox revenue exceeding one-third of total ARR — but the 15.5x ARR multiple is stretched, three major outages in May–June 2026 signal reliability risk, and complete opacity on gross margin and NRR prevents a buy call at the current price.
Deepgram appears to be a credible category leader in real-time voice AI, but the current $1.3B mark looks worth monitoring rather than aggressively underwriting until private financial denominators are disclosed.
Fresha has enough scale, product breadth, and profitability signal to merit active tracking, but public disclosure is still too thin and the >$1B mark looks stretched for a fresh buy.
Zenobē has real sponsor backing, operating proof, and infrastructure-scale relevance, but the public record is still too thin on economics and equity terms to underwrite a precise price.
ACS has unusually strong early military proof for a young counter-UAS startup, but the $2.2B Series B is ahead of public economic disclosure.
Pathos AI has assembled a credible AI drug development platform with strong pharma partnerships and a multi-asset oncology pipeline, but clinical and regulatory derisking remains early-stage with material key-person and concentration risks
Stoke Space's reusable upper-stage thesis is a real differentiator and its financing base is unusually strong, but a ~$3.42B secondary valuation already prices in significant execution before orbital proof, named customer conversion, or revenue disclosure are public.
EliseAI has crossed $100M ARR with dominant multifamily penetration and tier-1 backing, but a 22x ARR multiple and unresolved fair-housing regulatory exposure make the current price stretched for investors without regulatory diligence access.
Divergent has credible technical edge and defense-aligned market timing, but private-market pricing and sparse financial disclosure argue for a track stance rather than immediate conviction buying.
Base Power has a differentiated residential-battery plus retail-power model and real early Texas traction, but the latest $4B mark already prices in durable ERCOT economics and successful multi-state replication that public evidence does not yet prove.
Pathos AI has assembled a credible AI drug development platform with strong pharma partnerships and a multi-asset oncology pipeline, but clinical and regulatory derisking remains early-stage with material key-person and concentration risks
J&T Express is a scaled, profitable HKEX-listed express operator trading below prior private and IPO-era reference points; Buy for valuation, but only with medium confidence because China pricing, platform concentration, and governance risk keep the risk rating high.
Caris is a scaled precision-oncology platform with credible growth, improving profitability, and ample liquidity, but the stock looks closer to fair value than bargain territory while DOJ, reimbursement, and controls risks remain open.
Tulip is a credible industrial SaaS platform at the Series D stage with strong product differentiation and a strategic Mitsubishi Electric alliance, but revenue opacity and valuation premium at USD 1.3B require deeper financial diligence before conviction.
Delinea is a scaled identity-security platform with >$400M ARR, a broad product surface, and credible customer proof, but valuation and capital-structure opacity keep the name in track territory until a real pricing and disclosure event emerges.
Sysdig is the open-source-led CNAPP pioneer behind CNCF-graduated Falco, last valued at $2.5B in a May 2023 Series G, now navigating a more crowded and consolidated cloud-security market in which Wiz commands the agentless premium while Palo Alto and CrowdStrike bundle runtime security into platform sales; November 2024 layoffs and a 24-month financing pause warrant a conditional-buy / track stance pending verified ARR, NRR, and burn disclosures.
Figma is a market-defining design platform with best-in-class unit economics; selective buy below $38/share given limited margin of safety at current valuation.
Qonto has built the leading B2B neobank brand in France and is expanding profitably across Europe, but faces a valuation that implicitly prices sustained 20%+ growth in an increasingly competitive and regulated market.
Checkout.com is a technically differentiated, direct-acquiring enterprise payment platform with first-ever full-year profitability in 2025 and accelerating TPV growth, but the $12B valuation — a 70% discount from its 2022 peak — reflects genuine opacity risks from Jersey holding structure, key-person concentration, and the absence of new institutional capital for 3+ years.
Market-leading Indian bike-taxi platform with strong revenue growth and rapid loss compression, but elevated valuation multiple and persistent regulatory risk warrant a cautious buy stance.
Plaid is the structurally dominant US open-banking infrastructure layer with ~$546M estimated ARR, 70%+ market share, and accelerating product diversification, but private disclosure opacity, regulatory headwinds from CFPB Section 1033, and a Series D valuation overhang warrant a track stance at the current $8B implied valuation pending IPO S-1 confirmation.
Oura is the undisputed smart-ring category leader with clinical-grade biometric validation and a growing subscription revenue base, but the $11B valuation at an estimated 20-30x ARR is stretched and demands revenue and retention transparency before committing capital.
Redwood Materials has built a defensible position in US battery recycling with real technology, strong OEM partnerships, and critical IRA tailwinds, but faces substantial execution risk on its manufacturing scale-up and a challenging lithium price environment.
Mercury is a profitable, high-growth fintech banking platform with strong product-market fit among startups, a clear path to broader SMB expansion, and a defensible NIM-driven revenue model, but faces regulatory concentration risk from its partner bank model and growing competition from well-funded rivals.
Zepto is a high-growth Indian quick-commerce leader with strong revenue momentum and institutional backing, but faces significant profitability challenges and governance risks ahead of its IPO.
Vinted is a compounding European internet business — profitable, growing at 38%, with an integrated moat — but the April 2026 €8B secondary entry price (7.3x trailing revenue, 53x EBITDA) offers only modest base-case upside and material bear-case downside from regulatory and execution risks.
Vertically integrated autonomous weapons platform with deep DoD relationships; priced for perfection at $30B but uniquely positioned for defense AI secular tailwind.
Stord is a profitable cloud supply chain platform with G2 OMS leadership and $10B+ GMV — fair entry at $1.5B with 1.3–3x MOIC potential; favorable with material diligence conditions on churn, debt covenants, and SOC 2.
Invisible Technologies has genuine enterprise AI traction and credible product breadth, but the latest >$2 billion price already assumes stronger forward growth and software-like economics than public evidence currently proves.
Ualá has real regional scale, product breadth, and continuing sponsor support, but limited consolidated disclosure and Mexico credit risk keep the case at TRACK with high residual risk and a fair, price-sensitive current valuation.
Socure looks like a real, scaled identity-and-risk platform with unusually strong private-company growth evidence, but unresolved valuation, disclosure, and control-system questions keep the investment posture at track rather than buy.
Grafana is a genuine late-stage observability platform leader with open-source-led scale and >$400M ARR, but the last hard >$6B valuation still looks fair-to-stretched until private financial quality becomes more transparent.
Tanium remains a scaled, strategically relevant endpoint-security platform with credible post-2024 unicorn valuation support, but investment underwriting still needs refreshed ARR, margin, retention, and cap-table disclosure before the legacy $9 billion narrative can be treated as fully durable.
CONDITIONAL INVEST — Enterprise Sovereign AI at 29x ARR with Copyright Overhang
Anthropic has real frontier-AI demand and a defensible $380B headline mark, but public disclosure still falls short of a clean buy case.
A fast-growing LATAM identity-verification leader with real scale and revenue, but a stretched reported valuation, concentration, and biometric regulatory exposure warrant close tracking before conviction.
Galbot is a strategically credible but financially opaque Chinese humanoid robotics leader with real industrial deployments, world-class embodied AI, and state-backed capital — warranting close research and diligence before a commitment.
Kpler is a category-defining physical trade intelligence platform with a hard-to-replicate AIS data moat, confirmed rapid ARR growth, and 12,000+ enterprise customers—but the June 2026 Sixth Street entry at an implied 13–20x ARR multiple is stretched relative to public data-analytics peers, and zero disclosed unit economics (NRR, gross margin, churn) combined with the UK CMA antitrust review and a co-founder leadership transition prevent a buy call.
Basis appears to be a real category leader in agentic accounting automation, but the current valuation is ahead of what public economics can support.
Darwinbox shows real enterprise HCM momentum and a plausible path to $100M ARR, but public evidence still supports a TRACK / stretched stance rather than a clear buy at current pricing.
Quantexa is a scaled and strategically relevant Decision Intelligence platform, but public evidence supports TRACK rather than BUY until private diligence closes gaps on exact ARR, margin quality, burn, and the late-stage preference stack.
GlossGenius looks like one of the stronger beauty-vertical SMB software platforms in the U.S., but public evidence still leaves too much uncertainty on durability and economics to support more than a track posture at the unicorn valuation.
Semperis is the definitive identity-resilience platform for Active Directory and Entra ID, with $100M+ ARR, 1,000+ enterprise customers, and a durable AD-specific moat — but the $1B+ valuation at ~10x ARR is priced for continued high growth, and Microsoft bundling, opaque financials, and platform-consolidation pressure from CrowdStrike and SentinelOne make this a research-more rather than an outright buy at current price.
Bolttech has credible global embedded-insurance scale and strategic momentum, but public disclosure is still too thin to underwrite the June 2025 unicorn valuation with conviction.
Exabeam is the strongest independent SIEM/UEBA challenger thanks to its AI-native Nova platform, but near-term value depends on executing the LogRhythm integration without material customer attrition.
Bugcrowd is a genuine crowdsourced cybersecurity market leader—FedRAMP Moderate authorized, 1,200+ enterprise customers, 40%+ reported revenue growth, and a differentiated AI+human platform post-Mayhem acquisition—but the informal ~$2B valuation mark is stretched versus a base-case analysis of $1.2B–$1.7B, six critical diligence items remain unresolved, and financial opacity (no audited revenue, NRR, or gross margin disclosure) limits conviction; Track / Research-More pending data-room access.
Wireless Logic appears to be a scaled, profitable, strategically credible IoT connectivity platform, but the current private-market price still outruns the public evidence base.
Zum has built real late-stage scale in student transportation, but incomplete disclosure on margins, concentration, and EV project economics keeps the stock-story equivalent at research-more rather than buy.
Flatpay has rare SMB-merchant growth and a compelling simplicity pitch, but the public record still does not prove durable unit economics or enough disclosure to underwrite a €1.5B entry with high confidence.
n8n is one of the fastest-growing enterprise automation platforms in Europe, with compelling community moat, strong AI-native positioning, and institutional validation—but stretched Series C valuation and absent unit economics warrant a disciplined track rather than immediate buy.
Group14 is one of the most credible private battery-materials platforms in advanced anodes: it has real commercial deployments, a blue-chip strategic cap table, and a now-operating Korean production asset. But the underwriting case is constrained by BAM-2 execution slippage, policy and supply-chain dependencies, and sparse financial disclosure. On today's estimated valuation, the name looks interesting enough to track closely, but not yet de-risked enough to underwrite aggressively.
Chime looks like a scaled public consumer-fintech winner, but the current discount mostly reflects real sponsor-bank, regulatory, and disclosure risks rather than market misunderstanding alone.
Banco Plata's extraordinary growth — 3.4 million customers and USD 596 million annualized revenue in under three years — validates its model, but a 23.9% cost of risk, pre-profitability, concentrated wholesale funding, and a USD 3.1 billion valuation that demands sustained execution justify a TRACK stance until a clearer path to profitability and deposit funding is visible.
Writer has credible enterprise AI traction and differentiated full-stack product depth, but the $1.9B valuation already prices in sustained hyper-growth despite limited financial disclosure.
Track PathAI through Roche deal close: the strategic price looks reasonable, but standalone economics remain too opaque for a stronger call.
Underdog is a scaled consumer sports-gaming asset with real customer and revenue traction, but public evidence only supports a track recommendation because legal exposure and private-company disclosure gaps leave the current Series C valuation merely fair rather than clearly attractive.
Heartflow is a real, scaled public coronary-AI platform with strong growth, high gross margins, and meaningful installed-base proof, but at roughly 9x forward EV/revenue the shares already discount much of that quality before plaque economics, retention, and concentration are publicly visible.
Process Intelligence category leader at a stale $13B mark — track for IPO clarity, audited financials, and SAP-suit resolution before adding risk.
Saviynt pairs strong identity-security positioning and credible operating momentum with fresh KKR capital, but the current ~$3B mark still needs deeper diligence on round structure and audited economics.
Agibot is a credible production-scale humanoid robotics contender with a rare industrial proof point, but absent financial disclosure and growing geopolitical constraints justify a track-not-buy posture.
Employment Hero looks like a credible scaled SMB employment platform, but public disclosure is still too thin to underwrite the current private-market mark with high conviction.
Klarna is a scaled BNPL pioneer that reached public markets in 2025, but its post-IPO profitability path and regulatory headwinds in its two largest markets make the valuation case evidence-sensitive.
Insilico Medicine has the strongest clinical proof in AI drug discovery, but financial opacity and Phase 3 binary risk prevent a buy recommendation today.
Navan (NAAM) is a well-differentiated corporate T&E platform with strong NRR and expanding margins, but GAAP profitability has not yet been confirmed; CONDITIONAL HOLD at $18.46 with BUY trigger at $14-16 or first GAAP profitable quarter.
Isomorphic Labs holds the strongest IP position in AI drug design via AlphaFold 3 commercial exclusivity and three signed pharma partnerships, but its $16 billion private valuation embeds milestone-conversion assumptions unsupported by any public clinical evidence; TRACK pending ISM8969 Phase I data and first milestone payment.
ConcertAI is a conditional BUY at the ~$1.9B implied valuation; a differentiated multi-modal oncology AI stack and near-monopoly pharma penetration support the thesis, but unresolved CEO vacancy, opaque financials, and inability to verify the Goldman Sachs round from primary sources require blocking diligence before conviction.
Pentera is the clear AEV category leader at $100M ARR and a $1B valuation, but NRR opacity, competitive commoditization risk, and Israel-based operational exposure warrant rigorous private diligence before investing at current multiples.
Harness has real enterprise-DevOps traction and a credible AI differentiation story, but the 22x ARR entry multiple demands NRR, margin, and FedRAMP validation before conviction.
Pennylane is the category leader in French cloud accounting with a defensible dual-channel model and a regulatory tailwind, but the €3.6B valuation at centaur ARR implies a 30-35x revenue multiple that demands sustained 40%+ growth and successful international expansion.
Stegra is the most advanced large-scale green-steel project in Europe with strong customer commitments and ~€7.9B in disclosed financing, but pre-revenue first-of-kind construction risk, green-hydrogen cost uncertainty, and the recent €1.4B 2026 add-on raise keep underwriting confidence in the medium band.
Lightmatter is the leading photonic interconnect bet for AI infrastructure, but its $4.4B valuation demands near-term commercial proof that remains unverified; track with a focused list of diligence catalysts before committing.
KoBold Metals has built the most commercially validated AI mineral exploration platform in the world — as evidenced by BHP and Rio Tinto JV partnerships — and holds the Mingomba copper-cobalt deposit, one of the world's highest-grade undeveloped copper projects. The $2.1B Series C valuation is broadly defensible at base copper prices, but the investment requires patient capital (10-15 year horizon), carries above-average geopolitical risk (Zambia/DRC), and depends on an unverified AI performance premium. Recommendation: Conditional Hold — await the Mingomba Bankable Feasibility Study as the first major de-risking catalyst.
FourKites is a proven supply chain visibility leader with durable enterprise relationships and a credible agentic AI pivot, but limited financial transparency and a challenging late-2022 valuation anchor make a watchful track posture appropriate until a liquidity event or re-rate materializes.
WHOOP enters 2026 with credible IPO optionality, 103% bookings growth, and a $10.1B valuation that is rich but defensible against the closest private comparable (Oura) and anchored by positive free cash flow.
Meesho's zero-commission model and Tier-2/3 reach make it a structurally differentiated IPO at an attractive 1.4x EV/NTM Revenue, but thin take rate, profitability timeline, and intense competition from Flipkart and Amazon justify a selective accumulate stance rather than outright buy.
Research-more: Back Market is the undisputed global leader in refurbished electronics with proven unit economics and first profitability, but its 2022 peak valuation ($5.7B) has compressed meaningfully; secondary signals and multiple compression suggest a fair-value range of $4.5–6.5B, warranting deeper diligence on cap-table structure, competitive erosion in Germany, and IPO timing risk.
Maven Clinic is the category-defining leader in employer-sponsored women's and family health, with strong traction and clinical ROI evidence, but an unproven path to profitability and a $1.7B valuation that requires sustained 30–50% ARR growth to justify.
ClassDojo owns an unassailable K-12 distribution moat but its $1.25B valuation is stretched at ~12-13x unconfirmed ARR; the investment thesis requires Plus conversion acceleration and institutional SaaS traction to close a significant valuation gap before a 2026-2028 exit window.
Snyk is the defining developer-security platform with over $300M ARR and 4,478 customers, but faces material valuation compression risk, intensifying platform-native competition from GitHub and GitLab, and uncertainty around its IPO exit path given the gap between its 2022 peak valuation and current SaaS market multiples.
Collaborative Robotics is an early-commercial-stage AMR company with exceptional founding pedigree, strong enterprise customer proof, and a well-funded runway, positioned to compete in a large and growing warehouse automation market — but hardware economics, competitive pressure, and key-person concentration warrant a watchful posture with a conditional buy recommendation subject to financial and IP diligence.
Torq is the most credible pure-play AI-SOAR challenger to incumbent SOAR platforms, but the core thesis rests on an unaudited autonomous resolution claim and a 1–2 year window before XDR native AI triage commoditizes its Tier-1 value proposition.
Groq has compelling speed moat and developer traction, but the $6.9B valuation requires execution on $500M+ revenue and a successful Gen2 LPU ramp amid intensifying competition.
Huntress is the defining SMB MDR vendor with strong channel scale and product breadth, but its $1.5B+ valuation demands proof of ARR velocity and margin quality not yet in the public record.
Zipline is the drone delivery category leader with a verified operational track record, but the $4.2B Series F prices in US consumer unit economics that have not yet been demonstrated — a conditional positive for patient investors with regulatory risk tolerance.
Motive's AI fleet platform has real scale and strong customer proof, but IPO execution and an active Samsara trade-secret suit are the key overhang risks at $3.08B.
Chainguard has built the deepest supply chain security moat in the market — SLSA L3 provenance, nightly zero-CVE rebuild, and Wolfi OS represent 4+ years of engineering investment that is hard for CNAPP incumbents to replicate. Strong regulatory tailwinds (EO 14028, NIS2, DORA) and a growing developer-led pipeline support the long-term thesis. However, the 87.5x trailing ARR entry multiple is priced for perfection and leaves no margin for execution failure. Recommendation: HOLD — upgrade to BUY on confirmed FY2026 ARR ≥ $80M with NRR ≥ 120%.
Harvey is the defining legal AI franchise at an aggressive but potentially defensible $11B valuation — with elite customer anchors, deepening data moats, and a credible path to $1B+ ARR, but meaningful dependency, audit, and multiple-compression risks.
Preply looks like one of the more credible surviving edtech unicorns, but the $1.2B mark still needs private financial proof.
Vuori appears to be a genuinely strong and profitable premium activewear brand, but the last $5.5B mark still looks too expensive to underwrite confidently without audited financial disclosure.
1KOMMA5° has real scale and plausible software upside, but public evidence still supports a RESEARCH-MORE stance because valuation support, preference terms, and realized Heartbeat economics remain too thin for a conviction buy.
Rokt merits tracking at the US$3.5 billion secondary valuation because public evidence supports scale, growth, and strategic breadth, but private-company opacity prevents a higher-conviction underwriting call.
Anaconda is a real, profitable Python platform with enterprise reach, but the public evidence still falls short of underwriting the last round with high conviction.
Lighthouse looks like a category-leading hospitality software platform, but public evidence is still too thin on audited growth, retention, and capital-structure terms to support a full buy recommendation at the last unicorn mark.
BioCatch is a scaled, sponsor-backed fraud platform with credible bank traction and a more supportable valuation than in 2024, but public evidence still supports only a track posture until private economics, concentration, privacy controls, and deal terms are verified.
Aragen is a credible scaled Indian CRDMO with improving disclosure and customer depth, but the last-round ~$1.4 billion benchmark already prices in much of the visible upside while execution, compliance, and utilization evidence remains incomplete.
Halter has built a credible category-leading livestock operating platform with real customer and product-scale proof, but public evidence still supports only a research-more posture at the $2B mark until private unit economics, governance, and welfare durability are underwritten.
Awardco appears to be a high-quality, capital-efficient HR-tech platform with a real product moat and meaningful scale, but the current >$1B valuation already assumes continued 30%+ growth that public data cannot fully verify.
VAST Data looks like a genuine AI infrastructure winner with real scale, strong ecosystem proof, and differentiated data-platform technology, but the current $30 billion valuation still requires private diligence on revenue quality, concentration, and cap-table terms before new money can be underwritten confidently.
Mech-Mind has real industrial-AI deployment depth and credible technical integration, but public disclosure still supports only a research-more stance at unicorn pricing.
OPay is a scaled and strategically important Nigerian payments leader, but limited audited disclosure, Nigeria concentration, and recurring compliance or fraud-control issues keep the case in track territory and make the reported IPO ambition look stretched.
DeepL is a real, scaled Language AI platform with premium enterprise positioning, but the last $2 billion private mark still looks stretched until audited revenue, margin, retention, and term- sheet evidence closes the remaining underwriting gaps.
Cohesity is a scaled post-Veritas cyber-resilience platform with a defensible official >$7B value anchor, but the equity case is not premium-underwriteable until debt, ownership waterfall, and cohort-retention disclosure improve.
Claroty is a scaled OT/CPS security leader with real strategic value, but late-stage entry remains hard to underwrite until current ARR, preference stack, and the absolute Series F valuation are verified.
Speak has credible AI-language-learning traction and real unicorn momentum, but public evidence still undersupports the $1B mark.
OnlyFans is a dominant and highly profitable creator-payments platform, but the current price already reflects material regulatory, payment, and governance risk.
Coralogix has real product breadth, customer traction, and funding momentum, but the public record is still too thin on revenue quality, retention, and cap-table terms to justify aggressive underwriting at the $1.6B mark.
Starling is one of the few profitable European neobanks, but public evidence supports a TRACK rather than BUY stance until post-fine regulatory rehabilitation, FY2026 profit recovery, and clearer Engine economics are visible.
Profitable multi-product consumer-credit platform with meaningful scale, but the 2025 private mark already prices in a lot of future execution.
Pudu Robotics combines real global deployment scale and strong category breadth with improving capital access, but public evidence still leaves too much uncertainty on revenue quality, margins, concentration, and round terms to underwrite the April 2026 unicorn valuation aggressively.
Sierra combines elite founders, exceptional early enterprise traction, and deep capital access, but the May 2026 $15.8 billion valuation leaves little margin for error without deeper diligence.
IQM is one of Europe's strongest quantum hardware assets, but the current de-SPAC entry still depends on unaudited revenue, a binary transaction close, and proof that sovereign-heavy deployments can compound into durable commercial economics.
Ayar Labs is the best-funded pure-play in-package optical I/O company, with a blue-chip strategic cap table, a working TeraPHY+SuperNova stack, and a credible 2026-2027 ramp window — but commercial revenue is unproven, NVIDIA and Broadcom's in-house CPO programs raise real competitive risk, and the exact Series D valuation premium versus Lightmatter and Celestial AI is hard to justify without revenue visibility. Track closely; not yet de-risked enough to underwrite aggressively.
Teamworks looks like the leading vertical software platform for elite sports — with unusually deep league penetration, a broad workflow suite, and strong AI-oriented acquisitions — but the current $1B+ valuation sits on top of a public record that is far richer on scale and fundraising than on revenue quality, margin structure, or integration economics.
Shadowfax is a scaled and now-profitable Indian logistics platform, but current public-market pricing and customer-concentration risk justify a TRACK stance rather than aggressive upside underwriting.
Loft Orbital has credible platform, constellation, and sovereign traction, but limited financial disclosure and execution dependencies keep the stock of evidence at track, not buy, around an approximately $1 billion valuation.
OLIPOP: Category-leading prebiotic soda brand with profitable growth, but litigation and exit risk cap near-term upside
Aikido Security is a credible developer-first security platform with strong growth and product breadth, but the $1B valuation is ahead of what retained public operating evidence can support.
Linear is a standout workflow product, but the public evidence base is still too thin to justify paying the last unicorn round price with confidence.
A profitable, fast-growing identity-verification leader whose quality is high but whose price is unconfirmed against a three-year-stale $1.5B mark.
Forrester EU Wave Leader MDR pureplay at the low end of the public-comp band, with the 2-year stalled Evercore sale process and rising Microsoft / CrowdStrike bundling pressure as the dominant adverse signals — MONITOR with conditional INVEST on sale-process close at base case plus NRR ≥95% and top-10 channel partner ARR <40%.
X-energy has assembled a uniquely deep advanced-nuclear package — Xe-100 HTGR plus TRISO-X fuel, DOE ARDP cost-share, Dow + Energy Northwest + Amazon offtake, an 11 GW orderbook narrative, and a fresh Nasdaq listing — but with no Xe-100 reactor yet built, Q1 2026 opex running ~2.5x revenue, undisclosed reactor economics, and a long licensing and FOAK construction path ahead, current valuation is a probability-weighted strategic option rather than a defensible cash-flow story, and the appropriate stance is research-more with attractive optionality and high execution risk.
A top-tier AI-inference asset with elite founders and hypergrowth, priced for perfection against ~50% margins and structural commoditization risk.
Erebor targets a credible post-SVB startup-banking gap, but its public operating proof still trails its multibillion-dollar valuation.
Bending Spoons looks like a real software compounder with rare scale and recurring-revenue quality, but leverage, incomplete segment disclosure, and recurring user-trust backlash keep the right call at research-more until the IPO file is fuller and priced.
Attractive category position and customer proof, but public evidence still supports research-more rather than a fresh aggressive entry because revenue support is opaque and the prior valuation already prices in a large share of the upside case.
Luma AI has documented product traction and a credible $4B private mark from a sovereign-backed investor, but zero revenue disclosure means the valuation cannot be underwritten confidently from public evidence alone.
Goodfire looks like a category-defining interpretability company, but the public record still does not justify underwriting the February 2026 valuation as a clear bargain.
Hightouch is a real late-stage winner in warehouse-native marketing software, but the $2.75B Series D looks too expensive to underwrite from public evidence alone.
Harmattan AI has assembled unusually strong sovereign-defense proof points for a two-year-old startup—dual MoD Programs of Record and a Dassault Rafale F5 partnership—but the lack of public financial disclosure keeps the investment case in research-more territory.
Calm is a scaled and durable mental-wellness brand with real consumer and sponsor reach, but private-company opacity, leadership-transition risk, and a stale 2020 US$2 billion valuation anchor keep the current stance at track rather than buy.
Varda has exceptional operational proof and a genuine dual-use platform, but the $1.58 billion Series D price requires private financial disclosure to underwrite at medium confidence and high risk.
JSW One Platforms has a credible full-stack industrial-commerce thesis and a strategically useful JSW Group moat, but the ~$1B valuation still depends on unaudited FY25 operating data and a fast- scaling credit/distribution model that carries meaningful execution and governance risk.
Decagon pairs real enterprise AI-CX traction and strong product depth with a valuation that has moved faster than the public denominator, leaving the current $4.5 billion mark hard to underwrite without private diligence.
Parloa's 150% NRR, 117% ARR growth, and blue-chip enterprise proof justify a premium, but the January 2026 Series D prices the company at ~58x ARR—a stretched multiple that leaves limited cushion for execution misses. Prudent stance is Research More until gross margin, GRR, and forward-growth evidence catch up to the $3B mark.
Liftoff Mobile holds a durable dual-sided marketplace position in mobile advertising, but AppLovin's data advantages and privacy headwinds create structural competitive pressure.
CompanyCam has built a defensible contractor documentation moat with 285,000+ users, proven 2x ARR growth to $68M in 2024, and Nebraska's first unicorn valuation—but a ~29x 2024 ARR multiple demands ongoing acceleration that public evidence cannot yet confirm, warranting a track posture pending current ARR disclosure.
OneTrust is the category-defining privacy-to-AI governance platform at a $4.5B last mark, but new capital is not actionable without confirmed NRR, EBITDA margins, and PE acquisition structure.
Kalshi's CFTC regulatory moat and explosive revenue trajectory are real, but the $22B Series F price embeds a favorable legal outcome for sports event contracts that is not yet in evidence, making the valuation stretched and the appropriate posture research-more until key litigation catalysts resolve.
Melio is a strategically valuable but still hard-to-underwrite SMB payments platform: Xero's deal confirms real scale and distribution value, yet the standalone economics remain too opaque to treat the strategic acquisition price as a reusable entry mark.
Carro is a scaled Southeast Asian automotive platform with visible profitability progress and credible IPO optionality, but opaque capital structure, missing customer / unit-economics disclosure, and rumor-heavy valuation talk keep the risk-reward in TRACK territory around the US$3.0 billion anchor.
SendCutSend looks like a high-quality software-enabled manufacturing platform, but the May 2026 unicorn valuation already prices in a large share of the execution story while audited financials, debt terms, and preference-stack details remain private.
BuildOps is a high-growth commercial FSM unicorn with a defensible vertical niche, but the $1B valuation — ~10× estimated ARR with no disclosed NRR or gross margin — demands exceptional execution and demands caution at entry.
Truveta has a differentiated provider-governed health-data moat and meaningful genomics optionality, but current valuation already discounts much of the upside given opaque economics and material privacy and execution risk.
The Bot Company combines an elite founding team, exceptional capital formation, and a genuine product opportunity in household robotics, but the complete absence of product proof, revenue, or customer validation — combined with a $2B confirmed valuation, Cruise founder liability, and deep sim-to-real technical risk — justifies a TRACK stance at high risk with low confidence.
Suno has built an unusually large, fast-monetizing AI music business, but unresolved copyright exposure and opaque unit economics keep the verified $2.45 billion mark in track-only territory.
Trade Republic is a credible European neobroker decacorn with 10 million customers, €150 billion AUM, and three profitable years, but the June 2026 PFOF ban creates an unquantified revenue cliff, the €12.5 billion secondary mark implies a 25–31× estimated P/S that screens stretched, and private financial opacity precludes independent valuation verification.
TravelPerk is a rare late-stage SaaS unicorn achieving EBITDA break-even alongside >50% revenue growth, but gross margin opacity and an undisclosed-NRR gap prevent high-conviction underwriting at the current 13x revenue multiple.
Platform Science holds a structurally differentiated OEM-native moat in fleet management SaaS, with named enterprise customer proof at scale, but undisclosed financials and OEM channel concentration limit conviction; recommendation is Research-More pending financial diligence.
Alumis enters 2026 as the best-in-class oral TYK2 inhibitor pre-NDA story with Phase 3 PASI 90 of ~65%, $569.5M cash runway, and a strong-buy analyst consensus implying ~60% upside; a buy at $3.16B market cap with medium confidence reflecting single-asset binary FDA risk.
Bolt is Europe's most credible Uber challenger with proven cashflow-positive super-app economics, but the IPO thesis faces a material £200M+ UK legal liability and an EU labour-cost restructuring cycle that investors must model before committing.
Flutterwave is Africa's most significant payments infrastructure franchise with $26B+ annual TPV, but the $3B last-round valuation is stretched relative to current comparable multiples and the company carries unresolved regulatory, security, and IPO-readiness risk.
Lyra Health is the category leader in employer mental health benefits with 20M+ covered lives and strong brand recognition, but its $5.58B last-round valuation requires 20-30x ARR multiple justification that current market conditions and competitive dynamics make difficult to sustain.
Thunes' broad regulatory license stack (MAS, FCA, ACPR, HK MSO, 50-state US MTL), proprietary Direct Global Network across 130+ countries, and stated positive EBITDA at Series D position it as one of the most credible private B2B cross-border payments infrastructure platforms, but the absence of any disclosed Series D valuation, audited financials, or quantified retention metrics keeps conviction in track territory until data-room access is available.
Mujin holds a defensible motion-planning software moat in Japan's automation boom but faces opaque financials, US market immaturity, and intensifying AI-native competitors that temper conviction.
Vestiaire Collective is the leading European luxury resale unicorn with strong brand positioning, a Kering strategic relationship, and a sustainability narrative resonating with younger luxury consumers, but its $1.7B (2021) valuation looks stretched against public comparables and its path to profitability remains unconfirmed.
GreyOrange is a global warehouse robotics unicorn with a differentiated AI orchestration platform, but faces intense competition, hardware capital intensity, and limited financial transparency that warrant a 'track' stance pending revenue disclosure.
Devoted Health is a credibly executing, founder-led Medicare Advantage payvidor with category-leading Star Ratings and a 121% YoY member-growth print, but its ~$13B private mark trades at a 3-4x EV/Revenue premium to distressed public MA comps and depends on continued capital, V28 risk-model absorption, and a turn to consolidated profitability that state filings have not yet shown.
Cerebras has built a genuine hardware breakthrough in WSE-3 with the world's fastest AI inference, but 86% revenue concentration in a CFIUS-scrutinised customer and a delayed IPO create existential risk alongside the compelling technical moat.
Headway is the structurally strongest position in insurance-native behavioral health tech with 34,000+ providers and 45+ payer contracts, but the $2.3B Series D valuation prices in significant execution on Medicare/Medicaid expansion and reimbursement rate stability — both of which carry material regulatory and payer-concentration risk. Conditional positive pending financial disclosure diligence.
Astranis has built the only commercially validated small-GEO dedicated-capacity satellite product with five named customers, a government anchor contract (PTS-G), and $455M Series E runway — but the high-risk profile (anomaly track record, unproven manufacturing scale, capital intensity, ITAR obligations) and price-sensitive Series E entry require completion of five specific diligence items before capital commitment. Recommendation: Conditional Proceed — begin primary diligence; do not commit without resolving insurance, manufacturing yield, PTS-G terms, ITAR audit, and IP freedom-to-operate.
India's largest contract-manufacturing marketplace at IPO inflection - underwrite the growth, price the losses, and gate the recommendation on DRHP customer-concentration and unit-economics disclosure.
High-growth cloud physical security platform with strong product-market fit but material risk overhang from 2021 breach, regulatory enforcement, and limited financial transparency.
1X Technologies has rare commercial traction in enterprise robotics with EVE, strong backing, and a compelling NEO consumer vision, but faces autonomy gaps, competitive pressure, and financial opacity that warrant careful diligence before a Series C commitment.
Antora Energy has best-in-class fundraising and technology credibility, but remains pre-commercial — no named customers, no disclosed revenue, and a hidden valuation cap.
Drata is the compliance automation category leader with strong integration moat, AI-native platform expansion, and 8,000+ customers — but financial opacity and stale $2B valuation require a data room before conviction can be established.
NEURA Robotics is Europe's most advanced humanoid robotics company with a differentiated cognitive architecture and strong strategic partnerships, but remains pre-revenue with high burn, intense US competition, and no confirmed large-volume customer commitments.
Nimble is a compelling warehouse robotics bet anchored by a $1B Series C valuation, FedEx scale distribution, and a self-supervised AI moat, but near-term risk is dominated by extreme FedEx concentration and unverified revenue/margin claims.
Nuro offers a credible and differentiated AV software licensing play in a hyper-growth robotaxi market, anchored by the Lucid-Uber partnership, but remains pre-commercial with material Lucid solvency and Uber multi-sourcing risks that warrant conditional entry at the $6B valuation.
Semgrep is an investment-grade developer AppSec platform with a genuine technical moat and strong developer adoption, but elevated competitive risk from GitHub GHAS and financial opacity prevent unconditional conviction — Conditional Interest pending data room confirmation.
Shield AI is the leading AI autonomy platform for defense with exceptional growth but trades at a stretched ~47x revenue multiple that prices in substantial execution risk on its X-BAT and Hivemind enterprise scaling ambitions.
Waabi's world-class AI founder and billion-dollar backing position it as an AV 2.0 contender, but a missed driverless milestone and full revenue opacity demand verification before investment.
Physics Wallah is India's most affordable and fastest-growing digital test-prep platform, with dominant market position and strong brand, but remains loss-making with key-person and exam-policy risks that warrant a watch-and-accumulate stance post-IPO.
Halcyon occupies a defensible niche in anti-ransomware with strong technical differentiation and rapid growth, but limited financial transparency and platform consolidation risk warrant a Track recommendation at medium confidence.
Scale AI holds a defensible position in AI infrastructure with strong government exposure, but faces customer concentration risk, a CEO transition, and a pivotal business model shift away from data-labeling.
Cato Networks is the Gartner-recognized single-vendor SASE leader with authentic architectural differentiation, strong mid-market momentum, and 4,000+ customers — but undisclosed NRR/margin data and an IPO-freeze create valuation uncertainty at the $4.8B asking price.
Octopus Energy pairs the UK's highest-NPS energy retailer with a $8.65B AI utility platform; entry at $9B is defensible if Kraken ARR and churn are verified — but the data-room gaps are blocking.
Axonius has durable CAASM leadership and government penetration, but the $2.6B flat valuation, CEO transition, and unresolved financial opacity demand private diligence before institutional commitment.
Cyera leads the cloud-native DSPM category with exceptional ARR velocity, but the $9B Series D is fully priced for best-case execution with no margin of safety for Series D investors.
Sword Health is the credible AI MSK leader with 2,500+ enterprise clients, FDA clearance, and cash-flow positive operations — but Hinge Health's post-IPO advantages and self-reported outcome metrics limit conviction at the stretched 16.7x ARR valuation. Track; re-enter at $350M+ ARR with independent validation.
Whatnot has built the US live collectibles commerce market — $3B GMV, authentic seller community, unique break room product, and pre-sale authentication moat — but its $11.5B Series F valuation at 33× estimated revenue leaves minimal margin of safety for new investors. The base-case exit scenario (25–35% GMV CAGR through 2027, exit at 3–7× revenue) implies negative returns from Series F entry. TRACK until valuation reset, profitability timeline visibility, or TikTok Shop US regulatory resolution changes the risk/reward.
Mistral AI is Europe's leading open-source AI company with a sovereign AI moat, MoE compute efficiency advantage, and ~$200M ARR. The $6B valuation at 30x ARR is fair for 100%+ ARR growth but carries high risks from Big Tech resource asymmetry and undisclosed financials. Track for Series C entry.
Gecko Robotics has real strategic traction in defense and energy, but the public record is still too thin to justify paying the last $1.25B price with confidence.
Marvell paid $3.25B upfront for the most technically advanced silicon photonics scale-up interconnect asset available at a critical inflection point. The acquisition thesis — converting Celestial AI's Photonic Fabric into $500M+ ARR by FY2028 via Marvell's hyperscaler relationships — is coherent, but rests on a pre-revenue foundation with 18+ months of execution runway before revenue recognition. The 6.5x 2-year forward ARR multiple is at the conservative end of AI silicon comps, making the upfront price defensible if the earn-out milestones are achieved; the $2.25B contingent consideration appropriately aligns incentives. Risk rating is high given technology, timing, and talent execution variables.
Talos is a strategically strong institutional digital asset infrastructure platform with credible product breadth and customer traction, but its current valuation already prices in substantial future execution while public disclosure remains too thin for high-conviction underwriting.
Moneyview has enough scale, profit, and IPO readiness to stay on the active watchlist, but DLG exposure, partner concentration, and incomplete durability disclosure keep the right stance at track rather than buy.
Preferred Networks remains Japan's most credible vertically integrated AI platform, but a thinly disclosed revenue base and a conflicted ($1.0B vs $2B+) third-party valuation make the headline unicorn price hard to underwrite from public evidence alone.
Genspark's pivot from AI search to agentic workspace is compelling, but public disclosure still lags the valuation narrative.
Assured looks strategically credible in AI claims automation, but incomplete public operating disclosure and a full unicorn price keep the investment posture at research-more rather than buy.
Lovable has rare growth velocity, a compelling prompt-to-production product wedge, and real enterprise signal, but public evidence still does not support buy-grade confidence at current prices because enterprise mix, retention, margins, headcount, and cap-table terms remain too opaque relative to the valuation climb.
Pivot Bio has genuine agronomic proof and meaningful commercial reach, but opaque economics, regulatory uncertainty for next-generation products, and a stretched current mark keep the name in research-more territory.
N26 has re-established growth and a credible path to sustainable profitability, but ongoing supervisory pressure and stale private-market price discovery make the current valuation case investable only with caution.
CHAOS is a serious distributed-radar defense startup with real procurement-path signals, but the public record is still too thin on revenue quality and customer economics to support the latest price without more diligence.
Avathon has credible industrial AI product breadth, government traction, and sector-specific customer proof, but unresolved financial opacity and conflicting valuation signals make it a research-more opportunity rather than an invest-now conviction call.
Mambu appears to be a real, strategically relevant cloud-banking and payments infrastructure platform, but the lack of current financial disclosure leaves the public investment case attractive only at a meaningfully lower entry point or after deeper private diligence.
Nirvana shows credible AI-native underwriting momentum and fresh Series D backing, but public disclosure is still too thin to underwrite the $1.5 billion valuation with conviction.
Garner appears to be a credible late-stage healthcare navigation winner with real scale and a differentiated data-and-incentives model, but the $2.74 billion Series E already prices in premium execution while public disclosure on margins, retention, and capital structure remains too thin for a clean buy call.
Clip has real strategic value as a scaled Mexican SMB-payments platform, but limited audited disclosure and a demanding $2 billion price keep the call at RESEARCH-MORE with medium confidence and a stretched valuation stance.
At-Bay has built a credible InsurSec platform with meaningful SMB distribution, own-paper underwriting control, and an emerging security upsell engine, but public evidence still supports a research-more recommendation because underwriting, retention, and cap-table economics are not disclosed well enough to underwrite a clean entry near the estimated $2.1B mark.
ID.me is a real reusable-identity asset with national-scale reach, but the current >$2B private mark still runs ahead of the public evidence on revenue quality, margins, concentration, and policy durability.
Research more: Mynt / GCash is a systemically important Philippine fintech with real earnings contribution, dense customer reach, and broad product breadth, but the marketed IPO range is stretched until prospectus-grade disclosure closes the main financial, credit, and retention gaps.
Track Persona: it is a scaled, strategically relevant identity platform, but the $2B Series D valuation is stretched on public evidence until private ARR, retention, margin, concentration, legal-reserve, and cap-table diligence support it.
Serval has exceptional investor conviction and a credible AI-native ITSM architecture, but the unanchored revenue growth claim, all-tech-startup customer base, sub-30-person headcount, and complete absence of disclosed unit economics leave the $1B valuation impossible to underwrite from public evidence alone.
Track: Wave combines rare mobile-money scale and strong price-led adoption with limited financial disclosure, meaningful regulatory complexity, and stale public equity price discovery.
True Anomaly is strategically relevant and increasingly well-capitalized, but the public record still supports a cautious, high-risk, price-sensitive stance because mission proof outpaces economic disclosure.
Midi has built a scaled, insurer-friendly menopause telehealth platform, but the current unicorn valuation outstrips what public evidence alone can underwrite.
Scaled payer-connected mental-health platform with real network breadth, but the investment case still hinges on proving revenue quality and managing reimbursement-heavy execution risk.
StackAdapt looks like a real, scaled, and likely profitable adtech winner, but the secondary-heavy 2025 round, premium reported valuation, and incomplete financial disclosure keep the current underwriting case in the track-not-buy bucket.
Gradiant appears to be a real and strategically relevant premium industrial-water company with differentiated technology and strong market tailwinds, but the current $2B headline valuation already prices in much of the upside before investors receive audited financial disclosure.
HawkEye 360 looks strategically real—differentiated RF GEOINT capability, meaningful government traction, backlog, and new public-market liquidity are all visible—but concentrated public-sector exposure, backlog-quality caveats, capital intensity, and still-opaque recurring economics justify a track stance rather than a buy call at the current public valuation.
Airalo is a real, scaled leader in travel eSIMs with broad consumer and channel reach, but public evidence remains too thin on current revenue quality, margins, and downside terms to justify more than a track posture at the 2025 unicorn valuation.
Moon Active combines rare mobile-gaming scale with likely cash generation, but Coin Master concentration and private-company opacity keep the investment case in track rather than buy territory.
Oishii looks like one of the more credible survivors in indoor farming, but the public case still leans on brand and capital more than fully disclosed economics.
Thyme Care looks like a credible scaled oncology-navigation platform with real payer/provider traction, but public financial opacity and a likely stretched late-stage mark keep the current call at track rather than buy.
Creditas is a scaled Brazilian secured-credit platform with improving margins and strategic funding optionality, but it remains too opaque and rate-sensitive for high-conviction underwriting at the latest mark.
OpenEvidence has built unusually strong clinician adoption and a genuine premium-content moat, but the January 2026 $12 billion valuation runs far ahead of public evidence on revenue quality, advertiser durability, enterprise depth, and governance disclosure.
Aura has enough scale, product breadth, and partner distribution to merit continued diligence, but the combination of private-company opacity and trust overhang keeps the recommendation at research-more rather than buy.
PostHog looks like a real multi-product developer platform, but public evidence still does not justify paying the reported $1.4B price with discipline.
XBOW has unusually strong technical and ecosystem proof for a two-year-old cybersecurity startup, but the current valuation still outruns the public financial evidence.
Socket has real product-market fit in software supply chain security — strong AI/developer customer proof, transparent seat pricing, and a differentiated behavior-plus-reachability stack — but the May 2026 $1 billion Series C still looks slightly stretched on public evidence because ARR, retention, margins, burn, and cap-table terms remain undisclosed.
Go1 appears to be a scaled and strategically relevant enterprise learning platform, but the public evidence supports the business more cleanly than it supports the latest private valuation.
Bitsight is a category-defining cyber risk intelligence platform with real scale, strategic relevance, and a plausible valuation anchor around the last public $2.4B mark, but the lack of audited economics, current financing terms, and clear preference-waterfall disclosure supports a research-more recommendation rather than a clean buy call.
WorkOS is a high-quality developer-first enterprise identity platform with unusually strong AI-customer proof, but the $2B March 2026 round still outpaces the public operating disclosure needed for a conviction buy call.
Eight Sleep has credible product differentiation and a fresh $1.5B financing anchor, but opaque financials, trust-sensitive product risks, and a premium valuation keep the stockless underwriting case in track-not-buy territory.
BillionToOne merits a TRACK rating: the platform, growth, and liquidity are strong, but at roughly $3.95 billion and about 8.5x-8.8x 2026 revenue the shares look fairly valued versus unresolved reimbursement, litigation, and control risk.
Vention shows credible platform momentum, strong named customer proof, and a potentially valuable physical-AI position, but public evidence still supports only a track stance until financial disclosure and cap-table opacity are resolved.
Nexamp looks like a scaled and financeable community-solar platform, but current public disclosure is too thin to underwrite the equity confidently.
SafetyCulture is a credible frontline-operations category leader with real scale, but the AU$2.5B headline price implies a 15-21x ARR multiple that outruns peers and the disclosure package.
Shiprocket combines real platform scale, improving unit economics, and strong cohort stickiness, but litigation overhang, courier concentration, and a stretched $1.21B private mark justify a TRACK stance until IPO pricing is visible.
Aidoc is a credible scaled clinical-AI platform, but public evidence is still too opaque on price and economics to support more than a research-more stance.
Aqua Security remains a credible CNAPP pioneer with Trivy-driven distribution, runtime/container depth, and real enterprise reach, but flat valuation since the 2021 unicorn round, 2025 restructuring, and persistent private-company disclosure gaps justify a TRACK recommendation and stretched valuation stance until private diligence proves materially stronger ARR, retention, margin, and cash-efficiency than the public record.
Vectra AI appears strategically valuable and commercially credible, but the absence of current financial and cap-table disclosure makes the stock-selection equivalent call a disciplined track rather than an investable buy.
Included Health looks like a credible late-stage digital-health platform with product breadth, marquee buyer proof, and visible profitability, but the lack of audited financial disclosure, retention transparency, and fresh price discovery keeps the investment case in research-more territory.
Together AI shows credible inference-cloud product and traction at a Series B valuation that requires multi-year ARR scale to underwrite a strong exit.
RELEX has rare ARR durability and deep retail vertical moats, but the unadjusted 2022 valuation and April 2026 workforce reduction create material diligence asks before re-entry.
Guild Education built the largest employer-sponsored tuition benefit platform in the United States, anchored by IRS Section 127's structural tax subsidy and a multi-sided network of 500+ employers and 150+ education institutions. The June 2022 Series F at $4.4B represented a peak valuation reflecting COVID-era labor shortage tailwinds and edtech enthusiasm. Since then, the business has navigated two large-scale restructurings, high-profile client cancellations (Disney, Macy's), and an unconfirmed Walmart Workforce Edge threat — while launching Navigator as the growth catalyst required to justify any premium to distressed public comps. At an implied current EV of $1.5-2B (secondary market), the investment case is a conditional buy at or below $2.0B: the structural market is intact, the platform has demonstrated utility at scale, but financial opacity, decelerated growth (~6% YoY), and execution uncertainty during the CEO transition prevent high-conviction commitment without data room access.
Ramp's 100%+ growth, 25,000 customers, and AI-native moat justify TRACK status; the $13B secondary valuation at 18–26× unconfirmed ARR is aggressive and demands primary diligence before conviction.
Mainspring has real strategic momentum and credible project proof, but public evidence still supports research-more rather than a price-sensitive buy call.
Arcadia looks strategically important, but current public evidence still does not support a clean entry-price decision.
Cyberhaven shows credible category leadership and enterprise traction, but the $1B Series D still requires private diligence on financial quality, litigation exposure, and architecture hardening.
Black Lake appears to have real product-market fit in China's cloud manufacturing software niche and a credible industrial-AI upsell story, but the company still discloses too little about revenue quality, retention, and cap-table terms to justify an invest-now call at its April 2026 private-market valuation.
Tianji has real commercial momentum and technical differentiation, but sparse financial disclosure and a stretched unicorn valuation make it a track-not-buy story for new capital today.
Amca has a credible industrial thesis and meaningful early scale, but the $1B-plus mark is hard to underwrite without audited financials or customer-concentration disclosure.
Track: K2 Space has stronger contract proof and more differentiated product ambition than most private satellite manufacturers, but the $3 billion entry price still requires on-orbit validation, manufacturing execution, and much better financial transparency.
Vantaca appears to be a category leader in HOA/community-management software with credible growth, real product breadth, and a validated 2025 financing anchor, but public disclosure is still too thin to justify an aggressive underwrite at the last unicorn valuation.
Higgsfield has real hypergrowth and product-market pull in AI video marketing workflows, but the current underwriting case is constrained by unresolved safety, governance, and quality-of-revenue risk.
Forus has built a real prescription-access network with strong growth and strategic value, but the reported $1B valuation remains hard to underwrite without margin, concentration, and governance disclosure.
Periodic Labs combines one of the strongest founder teams in frontier AI and materials science with an ambitious autonomous-lab thesis and exceptional investor validation, but the company remains far from commercially proven and the reported 2026 financing mark prices in success well before public revenue or customer evidence justifies it.
Real multi-orbit orchestration proof and a credible government-commercial wedge, but the $1.3B round already prices in software-like upside ahead of disclosed economics.
Strategically relevant AI-native financial crime platform, but the current valuation is difficult to underwrite without private revenue, retention, and term data.
SKIMS has reached real global brand scale and category relevance, but the current $5 billion private valuation already prices in continued hypergrowth while audited financials, governance detail, and celebrity-concentration risk remain unresolved.
Forus appears to be a real and strategically valuable prescription-access workflow asset, but the public evidence is still too thin to justify paying the current unicorn valuation with conviction.
Aurora Solar appears to be a genuine category leader in solar workflow software, but public evidence still points to stretched valuation, market-driven operating pressure, and too much missing financial disclosure to underwrite the company confidently at its benchmark.
Fireblocks is a real institutional digital asset infrastructure leader with verifiable enterprise scale, but the unchanged $8B Series E mark is indefensible at current 4–6x EV/revenue multiples implied by BitGo's IPO and Anchorage's financing, and the company's continued opacity on margins, NRR, and litigation resolution makes a research-more call the only defensible position.
Zelos appears to be a real, unusually scaled autonomous-logistics operator with strong partner-backed deployment proof, but hidden economics, mixed valuation reporting, and unresolved legal/governance questions keep the case in research-more territory.
OnX appears to have built a real, scaled outdoor-mapping subscription platform, but the public record still lacks enough revenue-quality, retention, and term disclosure to underwrite the July 2025 ~$1.4B valuation with conviction.
Retool has credible product-market fit and strategic relevance in governed internal software, but the last disclosed $3.2B valuation still looks stretched against 2026 public comps and the company's thin public financial disclosure.
Razorpay looks like one of India's strongest private merchant-fintech assets, but the public record still supports tracking and further diligence rather than paying the highest private valuation headlines with conviction.
Poolside has a credible sovereign-enterprise product thesis and meaningful upside if secure coding AI becomes a durable high-ACV category, but public evidence is still too thin on revenue quality, customer proof, and infrastructure execution to support an aggressive buy recommendation.
Real payer-workflow scale, but undisclosed price and economics keep Cohere in research-more territory.
Castelion combines rare DoD demand pull, credible founder-market fit, and a manufacturing-first thesis that could matter if the Pentagon truly shifts hypersonics from boutique programs to mass procurement, but the current ~$2.8B valuation already prices in substantial execution and production success.
Redpanda combines strong Kafka-compatible technology, blue-chip production references, and real market tailwinds, but the April 2025 $1B Series D price remains difficult to justify without disclosed unit economics or independently corroborated scale metrics.
MNT-Halan has built genuine late-stage fintech scale, but incomplete disclosure on credit quality, margins, and capital structure keeps the investment case in research-more territory.
Handshake looks like a real category leader in early-career recruiting with meaningful platform optionality, but the public evidence is still insufficient to underwrite the stale 2022 unicorn price with confidence.
Marshmallow has a real and differentiated UK-newcomer insurance franchise with credible scale and a 2024 profitability inflection, but the >$2B 2025 mark still outruns the public disclosure needed for a buy call.
Strava is a scaled, premium-capable social fitness network, but the latest private-market mark still looks rich relative to what public evidence proves.
Clio is a scaled, profitable legal-workflow leader with genuine product breadth and customer reach, but the current US$5 billion valuation (about 10x ARR) and persistent disclosure gaps support only a track stance.
Radiant Nuclear has become one of the most credible private microreactor developers on public milestone evidence, but the current >$1.8B valuation signal still looks premature relative to zero disclosed revenue, stacked fuel and licensing gates, and concentrated customer proof.
Upwind looks strategically relevant and commercially real, but the current $1.5 billion valuation is ahead of what the public record can actually underwrite. Recommendation: research-more until private diligence closes ARR, retention, margin, and cap-table gaps.
Skydio has built a durable U.S. defense/public-safety drone position, but the April 2026 $4.4B price still assumes software-grade economics that public evidence does not yet prove.
o9 has credible product depth and strategic value in enterprise planning, but public evidence still falls short of justifying an unqualified positive call at the last disclosed $3.7 billion mark.
Fanatics is a real, scaled sports platform with credible diversification optionality and public revenue anchors around $7B to $8B, but stale valuation marks, opaque segment economics, and cap-table uncertainty keep the investability call at research-more rather than buy.
OpenAI has real frontier-AI scale and demand proof, but the $852B entry mark still outruns the public disclosure package.
Avoca has genuine vertical AI traction and elite investor validation in an underpenetrated home-services market, but the $1 billion valuation on undisclosed eight-figure ARR creates too wide an uncertainty band to underwrite without data-room access — warranting a track posture until key unit economics are verified.
Rain has built a genuinely differentiated stablecoin payments infrastructure platform with rare dual-network card membership and striking growth metrics, but the $1.95B valuation demands revenue disclosure that remains absent, and Mastercard's acquisition of BVNK is a direct competitive threat that could reshape enterprise pipeline dynamics.
Decart has built rare momentum in real-time world models and AI infrastructure, but the current ~$4 billion valuation is ahead of what the public revenue record can yet support.
Yinwang is strategically important and clearly scaling, but its RMB 115 billion mark already prices in a great deal of upside before standalone economics are publicly provable.
Ninja has achieved unusually fast Saudi quick-commerce scale and a credible pre-IPO profile, but incomplete disclosure on revenue quality, margins, and governance keeps the current $1.5 billion mark in track-not-buy territory.
Flexiv is a credible Stanford-pedigreed adaptive-robotics franchise with a differentiated force-control stack and unicorn financing, but private disclosure and US-China geopolitics keep the valuation hard to defend.
Clay has achieved exceptional product-market fit, capital efficiency, and community moat at $100M ARR, but the $5B tender-implied valuation embeds unverified NRR and gross-margin assumptions that prevent a conviction buy without data-room access.
HistoSonics has rare private-medtech proof for a first-of-kind non-invasive tumor platform, but missing commercial economics and a full 2025 valuation anchor leave it in research-more territory rather than justify fresh capital at current terms.
ShopMy has built a credible, fast-scaling creator-commerce platform with real platform-sales and profitability signals, but the public record still supports only a track stance because the latest $1.5 billion valuation sits ahead of disclosed fundamentals and detailed financing terms.
Sonatype appears to be a credible, profitable software-supply-chain control-plane asset with strong regulated-enterprise proof, but private-equity opacity, bundled-platform competition, and incomplete debt and retention disclosure keep the report in research-more territory.
Tipalti is a real scaled fintech platform with broad product depth and strong customer adoption, but the combination of regulated payments exposure, debt-funded expansion, layoffs, and a stale 2021 valuation anchor makes this a research-more name until management proves current economics and fair value.
Performance Drone Works shows credible defense-market traction, product breadth, and manufacturing ambition, but public evidence is still insufficient to price the business confidently because revenue, backlog, margin, headcount, and post-money terms remain opaque.
Render has real product breadth, strong developer adoption, and a credible AI-native wedge, but public monetization evidence remains too thin to comfortably underwrite its $1.5B valuation.
Salt Security remains a credible API security category pioneer with meaningful enterprise traction, but the gap between public operating disclosure and the 2022 unicorn valuation is still too large for a high-conviction investment call.
Voodoo has rare private-company scale and confirmed profitability, but opaque unit economics, B-rated leverage, and an unproven BeReal bet make this a track / research-more at any premium multiple.
Lunar is a real integrated battery and Gridshare VPP platform with meaningful traction and capital access, but opaque economics, California- and partner-heavy exposure, and conflicting valuation signals keep the right call at research-more.
Owner appears to have built a real and increasingly scaled restaurant-software platform for independent operators, but the public record still does not provide enough denominator detail on revenue quality, retention, margins, or financing terms to justify underwriting the May 2025 $1B valuation with conviction.
LangChain is a category-defining agent engineering platform with real enterprise traction, but the last disclosed revenue range still falls far short of supporting the 2025 $1.25B price from public evidence alone.
Liquid AI has differentiated edge-deployment technology and credible strategic backing, but the $2.3B private valuation still outruns the public commercial disclosure package.
Framer looks like a real design-led website-platform winner, but the current $2B valuation already prices in strong enterprise conversion and leaves too little disclosure on retention, margins, and revenue mix to justify an aggressive entry.
Moglix is a scaled, improving B2B industrial-procurement platform at an inflection point, but the $2.5–2.6B last-round valuation remains stretched relative to public comparables; track pending profitability confirmation and IPO-readiness disclosure.
Skyryse has built a differentiated software-defined flight-control platform with real certification progress and credible dual-use partner pull, but the $1.15B valuation already prices in substantial execution success before public revenue proof exists.
Strong outcomes and category momentum make Pomelo worth tracking, but public evidence does not yet justify confident underwriting at a $1.7B valuation.
osapiens has enough growth, product breadth, and customer proof to justify continued diligence, but the public record still does not defend paying above a $1B valuation with conviction.
Iterative Health shows unusually strong public proof of network performance and strategic relevance, but the current unicorn valuation still requires revenue and margin evidence that has not been disclosed.
Lila is one of the best-capitalized AI-for-science startups in market, but the current valuation already assumes scientific and commercial proof that the public record has not yet fully shown.
MiniMax has built one of the broader product surfaces among private AI companies and appears commercially real at meaningful scale, but live IP litigation, governance and financial opacity, and intense pricing competition keep the story in Track rather than buy territory at reported late-stage marks.
Whop has real creator-commerce scale and increasingly differentiated payments rails, but the February 2026 $1.6B mark already prices in premium execution despite limited audited disclosure and live trust, moderation, and dispute-handling risk.
Flock Safety is a real, scaled public-safety platform, but the 2025 round already prices in a favorable margin-and-trust outcome that the public record does not yet prove, so the right call remains TRACK rather than buy.
Zama looks like the clearest public leader in FHE-based confidential blockchain infrastructure, but the current valuation sits ahead of disclosed commercialization proof, supporting a research-more stance rather than a buy call.
Zip has credible product-market proof, category leadership signals, and large-enterprise customer traction, but the current $2.2B reference valuation is stretched against publicly unverifiable revenue quality and still-opaque financing terms.
Cera has real AI-enabled home-care scale and credible public-sector demand, but debt-heavy financing and incomplete disclosure support a watch posture rather than an aggressive entry.
Quantinuum is one of the strongest pre-IPO quantum platforms, but a $10B valuation on only $30.9M of 2025 revenue, a $192.6M net loss, and unresolved Honeywell control terms keeps the name in track territory rather than buy territory.
Enveda's Phase 1b ENV-294 data and $517M capital base establish real clinical credibility, but a binary Phase 2a readout, undisclosed financials, and an unconfirmed unicorn valuation keep it in watch-and-track territory.
Bedrock Robotics has credible early field proof and a strong autonomy pedigree, but its valuation already prices in execution that public economics and retention data do not yet verify.
Chai Discovery is a technically credible AI antibody platform with blue-chip backers and a landmark Lilly partnership, but its $1.3B valuation is entirely premised on unvalidated preprint benchmarks, a single disclosed revenue partner, and zero public financial data—warranting deeper diligence before any commitment.
Rapyd is strategically credible after PayU and clearly has real global payments scale, but opaque standalone disclosure, multi-entity execution risk, and only fair value at the 2025 mark support a TRACK recommendation rather than a buy.
Sakana AI is the leading Japan-native AI research company with production deployments at MUFG, SMBC, and ATLA, but its $2.65B valuation at ~88x estimated ARR and unresolved AI Scientist quality concerns warrant a TRACK stance pending third-party product audits and pricing normalization.
Koloma is the best-funded natural hydrogen explorer worldwide, backed by tier-1 climate and energy investors, but remains pre-revenue with unconfirmed well results and significant geological, commercial, and regulatory uncertainty at a likely $600–900M implied valuation.
Kavak pioneered formal used-car markets across LatAm with a unique financing-integrated model, but a 75% valuation haircut, continued losses, heavy debt, and market exits reveal deep execution challenges that must be resolved before the company can justify its original unicorn premium.
Silverfort's agentless identity security architecture is genuinely differentiated and the market tailwind is real, but the $1.5B Series D valuation carries a 20–50% premium over public comps and cannot be underwritten at high conviction without audited ARR, NRR, and burn-rate disclosure — warranting a conditional-buy stance pending diligence completion.
Research-more: Xaira's science, team, and capital justify continued diligence, but public evidence and unknown pricing do not yet support underwriting a premium private valuation.
Generate is a rare AI-native biotech with a real Phase 3 asthma asset and strong post-IPO liquidity, but the stock already sits near fair value while revenue quality and late-stage execution risk remain unresolved.
Netradyne is a credible AI fleet-safety platform worth researching further, but public evidence is not enough to underwrite a premium valuation without private financial and legal diligence.
Airwallex's $1B+ ARR at 90% growth, $8B valuation, and 80+ licenses represent a CONDITIONAL WATCH at current stage; US expansion execution, financial transparency, and governance maturity are the key thesis-validation milestones before a formal commitment.
Skild AI is the early platform leader in hardware-agnostic robotics AI with genuine technical differentiation, but its $14B valuation at ~467x ARR leaves no margin for execution risk — warrant research-more pending audited economics and public benchmarks.
Transcarent has assembled a compelling post-Accolade platform (20M+ members, 1,700+ clients, >$550M guided combined revenue) led by a proven CEO, but the investment case hinges on unverified standalone financials, unresolved integration execution risk, and a $2.2B valuation that looks stretched against the sector's 2022-2024 de-rating. Defer commitment until FY2025 audited financials and post-merger churn data are available.
Apptronik is an AI-native humanoid robotics company with deep NASA heritage, a Google DeepMind partnership, and $1.28B in funding — but remains pre-commercial with no confirmed pilot-to-commercial conversions, a stretched $5B valuation, and significant competitive and scaling risks.
Einride is a commercially-validated autonomous freight TaaS company with blue-chip CPG references and 500K+ AV km — rich at 39-42x 2024 revenue; monitor with conviction entry on SPAC close with >$100M trust net proceeds.
Form Energy has real manufacturing and customer proof, but the public evidence package still stops short of a priceable underwriting case.
Perplexity AI: Fastest AI-Search ARR Ramp in History, Priced for Perfection at 40× ARR
Research-more: Transmit Security has credible enterprise product and customer proof, but its private valuation is still too opaque and too rich to underwrite comfortably from public evidence alone.
Quince's M2C model and >$1B revenue milestone are genuinely impressive, but the $10.1B Series E implies a 5–10x EV/revenue multiple the public record cannot support and active deceptive-pricing litigation adds binary legal risk — warranting a track stance until margin data and litigation resolution improve underwriting visibility.
Ricursive combines rare AlphaChip-derived technical credibility with extraordinary financing speed, but the company still lacks public customer, revenue, and benchmark proof sufficient to fully underwrite a $4B valuation.
LogicMonitor is a credible scaled observability asset with fair public valuation support, but unresolved capital-structure opacity, incomplete unit-economics disclosure, and residual security/reliability trust debt keep the recommendation at TRACK rather than BUY.
FieldAI combines elite field-robotics talent, strong investor validation, and a differentiated hardware-agnostic embodied AI stack, but the lack of audited financial disclosure and limited named customer proof make the $2B valuation difficult to underwrite from public evidence alone.
Metropolis has real scale, operational reach, and product optionality, but the current $5B valuation still looks stretched until EBITDA quality, leverage reduction, and regulatory overhang are materially de-risked.
Infinium has stronger public customer and sponsor proof than most electrofuels peers, but the current public record still supports a watchlist posture because price, plant economics, and delivered-volume evidence remain too opaque for a conviction entry call.
Interesting scaled operator, but public evidence supports caution because valuation still looks expensive relative to visible peers and visible disclosure.
Research-more: Loggi is a real, scaled Brazilian last-mile platform with credible breakeven levers, but the stale ~US$2B private valuation anchor and thin disclosure make the current case too price-sensitive to underwrite publicly.
HIF Global has real operating proof and unusually strong strategic backers, but public evidence still supports a research-more stance because commercial-scale execution, economics, and current price discovery remain too opaque.
Compelling physical-AI thesis with elite backing, but too little commercial disclosure to underwrite the $1.7B mark confidently.
OfBusiness is a real scaled and profitable industrial B2B commerce-plus-finance platform, but without fresh parent audits and a public DRHP it is only worth tracking near the roughly $4 billion secondary anchor, not the floated $6-9 billion IPO range.
Dexory has credible product differentiation, real customer traction, and strong investor support, but the public evidence still supports only a research-more stance because valuation and software-like economics remain under-disclosed.
Axiom Space is strategically important and has real execution proof, but the public file is still too thin to justify paying the 2026 rebound mark as clean common equity.
Faire has real marketplace scale and improving monetization breadth, but public evidence is still too thin on credit losses, margin structure, and partner dependency to justify more than a track posture at the current valuation.
Research more: Ascend Money has real scale, strategic sponsorship, and Thai virtual-bank upside, but valuation above the last $1.5 billion public anchor looks stretched until audited economics and current price discovery are disclosed.
Tempo combines elite strategic sponsorship and a credible stablecoin-payments product thesis with unusually thin public monetization and governance evidence, so the right stance remains research-more rather than paying up at the last reported valuation.
Verdiva is one of the best-capitalized private oral-obesity startups, but public-only evidence still supports a track posture because the valuation already assumes meaningful clinical success while key efficacy, CMC, IP, and financing details remain opaque.
Degreed has enough market relevance, customer proof, and product depth to merit continued diligence, but the public record is still too opaque on retention, runway, cap table, and current valuation to justify a buy recommendation in the tougher 2026 software multiple environment.
Distyl has credible proof that it can move enterprise AI workflows into production, but the public record is still too thin on revenue quality and durability to justify underwriting the $1.8 billion valuation.
Chapter appears to be a credible, fast-scaling Medicare-navigation company with partner-led distribution and strong public growth signals, but the current private price is hard to justify from disclosed evidence alone because valuation, retention, and capital-structure details remain opaque.
Polymarket is the dominant global prediction-market platform with credible institutional and regulatory progress, but governance concentration, market-integrity questions, and a valuation far ahead of disclosed fundamentals keep it in track territory.
Meter has a credible full-stack networking product and real customer proof, but the current ~$1B mark is hard to underwrite without revenue, margin, and concentration data.
EnerVenue has genuine chemistry differentiation and strong strategic financing, but revenue opacity and China-centered manufacturing keep the investment case in research-more territory.
Game Science proved with Black Myth: Wukong that a founder-led Chinese studio can ship a world-class premium hit, but single-franchise concentration, limited financial disclosure, and unclear sequel economics keep the investable posture at research-more rather than buy.
d-Matrix has a differentiated inference architecture and credible commercialization momentum, but the $2B Series C still gets ahead of public proof on revenue, customer depth, and durable deployment economics.
Creatio looks like a credible late-stage workflow-automation platform, but missing public denominator data keeps the 2024 $1.2B mark in stretched territory and the recommendation at research-more.
Apex has credible product, factory, and government-demand proof, but the public record still lacks backlog conversion, unit economics, and financing details; at the last disclosed >$1B mark, the right call is research-more with a stretched valuation stance.
FieldAI combines elite field-robotics talent, strong investor validation, and a differentiated hardware-agnostic embodied AI stack, but the lack of audited financial disclosure and limited named customer proof make the $2B valuation difficult to underwrite from public evidence alone.
Heven AeroTech has credible strategic momentum in hydrogen UAS through Blue UAS Select, an Army BOA, and a fresh $100 million Series B, but the public record still lacks the revenue, backlog, and reliability proof needed to comfortably underwrite the current $1 billion financing anchor.
Articulate is a scaled, high-quality corporate learning platform, but the stale $3.75B 2021 mark and major disclosure gaps keep the investment case in research-more territory rather than buy territory.
Fourier is a credible rehabilitation-robotics company with real installed-base proof and a technically serious humanoid program, but absent economics, customer-quality disclosure, and named paid humanoid deployments leave the current RMB 8 billion anchor hard to underwrite. Keep the company in research-more mode rather than commit capital at the public mark.
Electra has credible technology differentiation and unusually strong strategic backing for a pre-commercial materials company, but the investment case remains gated by demonstration-plant performance, capital-intensity, and undisclosed valuation terms.
Watershed looks like a premium climate-native enterprise platform with strong logo quality and product breadth, but opaque economics, policy whiplash, and a stretched $1.8B mark keep the public-evidence stance at research-more.
Veza built a differentiated authorization-centric identity-security asset and won credible enterprise adoption, but the public record tops out at an $808M April 2025 standalone valuation and an acquired status with undisclosed transaction terms. Treat Veza as a closed strategic-exit case rather than a current standalone unicorn, and require private ARR and deal-term disclosure before assigning any premium beyond the last public mark.
Multiverse has real enterprise traction and a fresh $2.1 billion price signal, but public evidence still supports a research-more stance because losses, policy-linked delivery risk, and disclosure gaps make the valuation look stretched.
Corelight is the credible open NDR leader with strong analyst validation, but an undisclosed valuation and opaque financials justify TRACK over BUY until key data room items are confirmed.
Helsing is Europe's most capitalised defense AI startup with proven NATO deployments, but a €12B entry valuation outruns public evidence on revenue, margins, and customer concentration.
Research-more: Cellares has unusually strong public customer proof for a private cell-therapy manufacturer, but undisclosed pricing and missing economics keep the investment case high-risk and price-sensitive.
Research-more: insitro has real partner proof and a plausible route to premium techbio value, but public evidence does not support underwriting an aggressive private valuation without clean terms and stronger clinic-ready proof.
sennder has the network scale and strategic anchors to be Europe's defining digital freight platform, but entry requires data-room access to validate profitability trajectory and CHR integration cost.
Bilt Rewards commands a $10.75B valuation on the first rent-rewards moat, but unit economics are unverifiable and the LoyaltyOne precedent warrants elevated caution.
Judi Health is building a structurally differentiated transparent PBM and unified claims platform at meaningful scale, but the $3.25B September 2025 valuation prices in substantial admin-fee revenue growth that has never been publicly disclosed, warranting a Track stance with medium conviction pending confirmation of unit economics.
Photonic has one of Canada's most credible private quantum architecture stories, but the public evidence still supports follow-up diligence more than price-insensitive conviction at a $2.0 billion mark.
Hithium has become a scaled global ESS battery contender with credible shipment and revenue momentum, but current public evidence supports a track stance rather than a buy because valuation clarity, litigation exposure, receivables quality, and IPO-readiness disclosure remain too thin.
Research-more: Standard Bots has a credible AI-native cobot product narrative and real customer anecdotes, but the June 2026 $1B valuation is too price-sensitive to underwrite from public evidence because revenue, margins, and deployment efficiency remain undisclosed.
Modular has real technical differentiation, fresh capital, and early customer proof, but public revenue, margin, retention, and cap-table disclosure remain too thin to underwrite a buy at the latest $1.6 billion valuation.
team.blue is Europe's best-capitalised SMB digital platform with a proven buy-and-build flywheel and Tier-1 PE backing, but complete financial opacity, a failed leveraged loan repricing, and a valuation multiple that implies a 3–5× premium to public European peers limit conviction to a "track" rating until the debt structure and revenue base are independently confirmed.
EGYM is an EBITDA-profitable global fitness-technology platform with $800M+ combined 2025 revenue, 75% subscription mix, and genuine network effects, but the 9.4× combined EV/revenue multiple is stretched versus public comps, and key underwriting drivers—NRR, gross margin, and post-integration unit economics—remain undisclosed in a fully illiquid private vehicle.
Pleo shows real product breadth, scale, and monetization progress, but the supportable public-data conclusion remains research-more because the latest mark still looks stretched against disclosed evidence and too many underwriting-critical operating metrics remain private.
BetterUp has credible enterprise product-market fit and meaningful scale, but limited disclosure and a still-demanding late-stage valuation argue for continued diligence rather than immediate conviction.
Carbon has real production-scale DLS proof and insider-backed runway, but opaque financials and a stale $2.4B valuation anchor make further diligence—not underwriting at face value—the right posture.
Highview holds a credible strategic position in UK long-duration energy storage, but valuation remains under-determined until Carrington proves commercial execution and private financing terms become clearer.
Versa Networks is a credible late-stage unified-SASE platform with meaningful channel and customer traction, but opaque financial disclosure, execution complexity, and a still-debatable 2024 valuation keep the current stance at research-more rather than buy.
Positron has credible early proof—real financing, named lighthouse customers, and a differentiated memory-first product roadmap—but at a $1B+ entry price with undisclosed revenue, margins, and security terms, the prudent stance is to track rather than underwrite the round as clearly attractive.
Epirus has credible Army proof and strong counter-drone tailwinds, but its likely down-round reset, opaque economics, and prime-backed competition keep the investment stance at track rather than buy.
New Limit combines elite capital access and unusually detailed preclinical progress with no human data, making it a high-upside but still high-risk research-more opportunity at the current price.
Vultr has credible independent-cloud and GPU-infrastructure positioning plus real financing validation, but the public record is still too thin on revenue, margins, debt terms, and customer quality to justify a clean buy at its last $3.5B mark.
Trendyol is the dominant Turkish e-commerce platform with decacorn GMV scale and domestic profitability, but its $16.5B last mark is five years stale, implying a 6.6–9.2x EV/Revenue premium to emerging-market peers, making it unattractive at the 2021 price with no confirmed exit mechanism.
Dataminr is a real, scaled, differentiated intelligence platform, but the unchanged 2021 valuation headline looks hard to underwrite after 2025 bridge-like convertibles and persistent disclosure gaps.
Enpal combines category-leading scale in German residential solar with a broadened home-electrification bundle and unusually deep structured-finance access, but opaque post-2023 valuation, limited audited profitability disclosure, service-quality/legal friction, and policy sensitivity justify a Track rating rather than an invest-now recommendation.
Ambience Healthcare leads the ambient AI scribe category but trades at a steep 42x estimated ARR multiple that leaves little margin for execution risk.
Hai Robotics is a real category leader in ACR-based warehouse automation, but the public record still supports tracking rather than buying because pricing, dilution, and recurring-economics disclosure remain incomplete while losses and concentration stay material.
Function Health has executed a textbook celebrity-physician DTC launch into the preventive-health market — roughly one million members and a self-reported $100M ARR in under three years, anchored by Mark Hyman's brand and Quest Diagnostics' nationwide lab footprint. The $298M Series B at $2.5B (~25x ARR) is stretched against public DTC-health comparables, the effective $100 ARPU is unreconciled against the $499 list price, and adverse press from the NYT Well desk, TIME, and independent scientific critics raises overdiagnosis, FTC endorsement, and laboratory- developed-test (LDT) regulatory questions. Track until unit economics, retention, and clinical/regulatory posture clarify.
Sila has real product and factory proof, but the absence of disclosed revenue, margin, and a confirmed valuation keeps it a price-sensitive track rather than an actionable buy.
MoEngage looks like a real, scaled engagement platform, but public disclosure is too thin and the late-2025 pricing too rich to support a buy call from public evidence alone.
Verkor is one of the more credible remaining European battery platforms because it has a live Dunkirk asset, Renault-backed demand, and €3B+ of committed capital, but the equity case is still too opaque and execution-sensitive for a buy call after Northvolt showed how fast battery-scale optimism can unwind.
Mura Technology is the first commercial operator of hydrothermal advanced plastic recycling, with best-in-class environmental credentials and KBR's institutional backing, but faces critical financial opacity, an outstanding IP security charge, and the Böhlen cancellation as adverse commercial signals.
EvenUp appears to be the category leader in plaintiff-side legal AI, but the >$2B valuation is hard to underwrite without audited ARR, gross margin, and retention data.
Tyme Group is a structurally credible emerging-market neobank with proven South African unit economics and Nubank's strategic endorsement, but information asymmetry — no consolidated group audited financials, unconfirmed Philippine profitability, and partial cap table disclosure — prevents a high-confidence buy recommendation on publicly available evidence alone; track and request group financials before committing.
Tamara is a credible, SAMA-licensed BNPL unicorn with strong Saudi alignment and a growing merchant network, but trails Tabby in scale, lacks financial transparency, and faces credit-risk opacity that warrants close monitoring rather than immediate conviction.
Helion Energy is the world's most commercially advanced fusion company, holding the only signed commercial fusion PPA (Microsoft, 2028), a $5.425B Series F valuation, and unique Faraday direct-conversion technology — but faces a binary outcome: net energy gain demonstration with Polaris by 2026-2027 is the single most consequential technical milestone in the history of commercial fusion.
BETA Technologies has serial-production tooling and named customers, but the public evidence package still hinges on FAA type-certification timing before a 2026 valuation mark can be underwritten.
Toss is Korea's most valuable private fintech with a proven super-app model and $330M+ revenue trajectory, but its $7.4B 2021 valuation faces compression from repeated IPO delays, a fintech market re-rating, and the challenge of growing into a multiple that requires sustained profitability none of its business lines has yet achieved at scale.
ShipBob has real operational scale and durable Shopify channel proof, but the stale 2022 mark against repriced 2026 public comps and undisclosed financials support research-more rather than a price-sensitive buy call.
Dragos is the category-defining OT cybersecurity platform with compelling threat intel moat; investment blocked by financial opacity and uncertain post-2023-layoff trajectory. Track for future entry if ARR >$70M confirmed at <$2B valuation.
Stack AV offers a compelling team and AV trucking thesis but remains pre-commercial with high capital intensity and unresolved regulatory, technology, and commercialization risks — warranting a Track recommendation.
1Password has a credible 150k-business-customer XAM platform and a defensible security architecture, but the $6.8B 2022 valuation has not been refreshed and unit economics remain non-public.
Nium's 40-license regulatory moat and $50B+ annual transaction volume position it as a credible B2B payments infrastructure IPO candidate, but India legal risk, 53% operating loss margin, and growth deceleration create elevated pre-IPO risk requiring active monitoring before increasing position conviction.
Fervo Energy is the global EGS leader with 658 MW of binding PPAs and a $7.2B backlog, but trades at an 87% premium to operational geothermal comparables on pre-commercial financials — the $6.5B IPO is only justified if Cape Station Phase 1 delivers on time.
Cognition AI is a category-defining autonomous software engineering platform with exceptional ARR growth ($1M → $73M in 9 months), but the $10.2B valuation at ~140× ARR prices in near-flawless execution in a market facing rapid benchmark commoditization and critical undisclosed financial metrics.
Neko Health has exceptional early demand metrics — 80% annual repurchase, 100,000+ UK waitlist, £299 price point — but its $1.8B Series B valuation is highly stretched at 360-600x estimated revenue and rests on clinical AI claims with no peer-reviewed validation. Track until clinical evidence and multi-city revenue prove the thesis.
Figure AI has done what no humanoid robotics company has achieved before: a proven, multi-month deployment at automotive production scale, with BMW manufacturing metrics that are independently corroborated. The $39B valuation prices in a future that requires displacing Tesla Optimus, Agility/Amazon, and every industrial automation incumbent — at 250–650x estimated revenue. The deployment proof is extraordinary; the valuation is extraordinary risk. Specialists with 7–10 year horizons and deep robotics domain expertise may find a speculative entry defensible; generalist growth investors should avoid at this multiple.
Valar is one of the fastest-moving U.S. advanced-nuclear startups, but public evidence still supports research-more rather than paying through its reported $2 billion 2026 mark.
Hermeus has real proof of life—Mach 1.21 flight, a $219 million DIU-backed defense pathway, and a blue-chip investor set—but it is still pre-production, economically opaque, and dependent on difficult Mach 3 / payload-release and acquisition-transition milestones, so the prudent stance is research-more rather than buy.
CMBlu combines credible long-duration storage differentiation and strategic capital with a valuation that currently runs ahead of commercial proof, supporting a research-more call rather than a buy.
Code Metal has a differentiated verification-first product and credible defense and industrial demand signals, but at the disclosed $1.25B Series B price the public KPI record is still too thin to underwrite without more diligence.
Wonder has assembled a credible multi-surface mealtime platform, but public evidence is still too thin on standalone economics and post-acquisition integration quality to underwrite confidently above the reported $7B valuation.
Startorus Fusion looks like one of China's more credible private fusion platforms, but the current unicorn valuation still depends more on milestone delivery, policy support, and future disclosure than on proven commercial traction.
Rebel Foods is a scaled, strategically relevant food-tech platform, but the public evidence still supports a price-sensitive watchlist posture rather than a conviction buy at the old unicorn mark.
MiRus has unusually strong strategic validation for a private medtech company, but the current price still depends on pivotal-trial success and private financial facts that public evidence does not yet supply.
Mind Robotics has a rare industrial data and capital wedge, but public proof still lags its multibillion-dollar valuation.
Solace has built a compelling, reimbursement-backed patient-advocacy platform with real national scale, but the public record still supports only a track stance because core economics, payer mix, and Series C terms remain too opaque for a clean late-stage underwrite.
GrubMarket has built a rare scaled hybrid of food distribution and vertical ERP software, but the SEC's revenue-overstatement settlement, acquisition-roll-up complexity, and still-thin audited disclosure make the current price a watchlist story rather than a buy today.
Avride is strategically relevant and commercially live across robotaxis and delivery robots, but the active NHTSA probe, partner concentration, and sparse financial disclosure support only a cautious track posture and a discount to headline unicorn narratives.
Xcimer pairs a differentiated laser-fusion architecture and strong early investors with real technical ambition, but no public valuation, no public customer proof, and very high technical and capital-intensity risk keep the name in research-more territory until milestone and commercial evidence materially improve.
Revel has a credible control-software wedge and unusually strong founder-market fit, but public metrics remain too thin to justify conviction at the third-party-reported $1B+ valuation.
Track: Udaan's turnaround is credible enough to defend a scenario-based $1.4-1.9B base case, but the current $1.8B mark is not a wide-margin-of-safety entry while revenue quality remains inventory-led and key runway, credit, and dilution inputs are still undisclosed.
Darktrace still looks like a scaled, strategically relevant cyber platform, but sponsor-era opacity on debt, governance, and current operating performance keeps the name in track rather than buy territory.
Credible legal-workflow leader, but the current ~$3B mark is ahead of public proof on margins, investor terms, and realized AI economics.
SumUp is a scaled and strategically relevant SMB-payments platform, but the public record still supports only a track call because economics, capital structure, and governance disclosure lag the valuation narrative.
Sierra Space is a well-capitalized but still under-disclosed space-and-defense platform whose $8 billion March 2026 valuation looks stretched until Dream Chaser converts its late-2026 demo into contracted demand and management opens the revenue, margin, and term-sheet denominator.
SambaNova has credible technical differentiation and sovereign/government traction, but opaque economics, customer concentration, and valuation ambiguity keep the equity story in research-more territory.
BigID looks like a real, strategically relevant late-stage data-security platform, but public evidence is still too opaque to underwrite aggressively above a disciplined secondary-entry price.
Electric Hydrogen has one of the strongest Western large-plant electrolyzer platforms, but its stale unicorn valuation still outruns proof of commercial conversion in a deteriorated green-hydrogen market.
Isar Aerospace combines unusual strategic relevance, capital access, and real launch progress for a European private launcher, but without orbital success, clean commercial disclosure, or transparent convert terms, it remains a research-more story rather than an underwritable buy.
Flex appears to have built a genuine distribution moat in rent-payment flexibility, but undisclosed capital structure, opaque credit economics, and a meaningful record of servicing failures keep the correct call at research-more rather than a price-sensitive underwriting.
Substack has genuine creator-platform scale and differentiated network effects, but the 2025 unicorn valuation looks expensive against estimated ARR, visible creator churn pressure, and elevated legal-platform risk.
Armada has a credible sovereign-edge infrastructure wedge and unusually strong early deployment proof, but opaque economics, factory-scale execution risk, and a stretched 2026 price keep the company in research-more territory.
Hunters appears to be a credible next-gen SOC platform with real enterprise logos and a differentiated vendor-agnostic architecture, but the absence of current financial disclosure and price discovery keeps the name in research-more territory rather than an investable buy.
Sunfire is a strategically relevant European electrolyzer scale-up with real industrial proof, but public-only evidence supports a research-more stance because economics, disclosure, and subsidy-linked project conversion remain too opaque to justify a full-price buy.
Mercor is a real frontier-AI workflow franchise with credible benchmark and software upside, but the $10B mark already prices in cleaner economics, better diversification, and stronger trust than the public evidence currently proves, so the right call is TRACK.
Chainalysis remains the category leader in blockchain intelligence with durable government traction, but the valuation reset and opaque private financials keep the call at research-more and the ~$2.5B mark only marginally defensible.
MUBI has a real premium arthouse brand, a rebound to 1.7M subscribers, and a differentiated streamer-curator-distributor model, but backlash sensitivity, hit-driven film economics, opaque segment margins, and a $1B mark justify a research-more stance.
Imprint appears strategically credible and commercially real, but incomplete disclosure, credit-and-funding intensity, and a stretched public valuation bridge support a research-more recommendation rather than a buy call.
Element has become a credible sequencing challenger with real commercial momentum, but at or above the last disclosed unicorn mark the public evidence still supports research-more rather than an immediate buy.
OPSWAT appears to be a real, scaled OT/IT cybersecurity platform with credible product breadth and customer traction, but public evidence is too thin to underwrite the rumored ~$1.8B valuation or form a high-confidence investment view without audited financials and cap-table disclosure.
Divert has assembled a defensible end-to-end food waste circular economy platform with genuine operational switching costs, but its $1B+ Series C valuation implies revenue well above two-facility run-rate reality and complete financial opacity precludes independent underwriting, warranting a track posture pending disclosure.
Alloy Therapeutics looks strategically relevant and partner-rich, but the current $1.0B mark already assumes durable economics that public disclosures do not yet substantiate.
Spirit AI has stronger technical and partner proof than most young embodied-AI startups, but the public record still does not justify underwriting the current valuation without deeper financial diligence.
RADAR has genuine first-mover scale and compelling customer proof in retail RFID, but the $1B price cannot be validated without ARR, gross margin, or NRR disclosure.
You.com has credible product breadth, customer proof, and capital access, but public evidence still underwrites relevance more convincingly than durable economics, leaving the $1.5B Series C mark looking stretched.
Xpansiv looks like strategically important climate-market infrastructure with credible unicorn price support and real workflow breadth, but persistent financial and cap-table opacity plus a fragile voluntary-carbon backdrop keep the correct public-markets posture at research-more.
Sunday pairs a differentiated real-home data loop and elite robotics pedigree with blue-chip financing, but the public record still lacks the price, customer proof, and unit economics needed to underwrite the $1.15 billion valuation.
Advanced Navigation appears to be a real, strategically relevant assured-PNT company, but the public record still does not support paying a late-stage unicorn-style price with confidence.
SpreeAI shows credible product, partner, and brand momentum, but public economics are too thin to justify the reported $1.5B valuation with conviction.
Deep technical moat, credible federal and financial-services wedge, but no disclosed revenue or valuation makes underwriting the $389M capital base speculative at any price.
Zepz is a real scaled remittance incumbent with strong corridor coverage and product optionality, but public-only underwriting remains weak because valuation, governance, and financial disclosure have not kept pace with its private-market history.
Mach Industries has credible defense-autonomy momentum, real manufacturing ambition, and enough Army-linked proof to stay on the radar, but weak revenue-quality disclosure and a stretched $1.8 billion Series C keep the name in TRACK rather than buy territory.
Trulioo is a high-quality global identity platform with re-accelerating revenue growth and strong enterprise proof, but the 4-year-stale $1.75B valuation anchor, unaudited financials, and leadership transition support a track rather than buy posture.
Windsurf built a strategically valuable AI coding platform with real enterprise traction, but the independent company has effectively been broken into talent, technology, and successor-product components, eliminating a clean new equity entry.
Blink has real national prescription-access reach and fresh Series D support, but opaque economics, conflicting private-market marks, and elevated regulatory and operational risk keep the case at research-more with a stretched valuation stance.
Thought Machine has real product differentiation, credible customer proof, and strong modernization tailwinds, but the public record still does not justify underwriting the stale 2022 valuation without materially deeper financial diligence.
Jumbotail has built a strategically relevant B2B commerce and new-retail platform for kiranas and MSMEs, but public evidence still shows wholesale-heavy, loss-making economics and elevated integration or control risk, so the current unicorn pricing belongs on a watchlist rather than in the portfolio.
ZaiNar has a plausible network-positioning wedge and unusual patent depth, but absent named partners, clean backlog quality, and disclosed unit economics, the current public record supports tracking rather than underwriting the $1B-plus mark.
Research-more: Nyobolt has credible product proof, strategic validation from Symbotic, and clear commercial momentum, but the May 2026 $1B valuation still looks stretched until diligence closes the revenue, margin, concentration, and preference-term gaps.
SandboxAQ is a technically credible Alphabet spinout with real government traction and elite investor backing, but a $5.75 B valuation at ~315× unverified ARR demands revenue confirmation before a buy case can be supported.
Talkiatry is the category-leading in-network telepsychiatry provider group with 800+ employed psychiatrists, broad payer coverage, and validated outcomes, but a labor-intensive W-2 model, fully undisclosed unit economics, prescribing-regulatory exposure, and an unconfirmed ~$1.4B inferred mark make it a track / research-more rather than an underwrite-now opportunity.
Proof has built the leading RON and identity-authorization platform with 7,000+ customers and real transaction scale ($200B+ annually), but the investment case is complicated by financial opacity, housing-cycle concentration, a 2022 restructuring, and a Forge secondary mark (~$987M) that implies double-digit revenue multiples versus public comps—without disclosed ARR, margin, or NRR evidence to validate the premium.
Curative has a credible employer-plan wedge, real 2025 financing validation, and enough public member scale to stay on the watchlist, but the current $1.275 billion mark still looks stretched because audited underwriting, reserve, and renewal data remain private.
Peregrine has exceptional growth credentials and Tier-1 investor validation but is priced at ~61x ARR — more than twice the concurrent Flock Safety comp — in a market with escalating civil-liberties risk and entirely undisclosed unit economics; conditional track pending ARR audit, NRR confirmation, and valuation step-down.
Job&Talent shows real operating scale, improving profitability, and credible AI workflow traction, but the 2025 down round and opaque capital structure leave the current entry price too demanding for a higher-conviction underwriting call.
Bitdefender is a real, profitable hybrid cybersecurity franchise with credible endpoint/XDR technology and global distribution, but private-company disclosure gaps, a consumer-heavy mix, and preference-stack opacity keep the case at research-more rather than buy ahead of any IPO.
Druva is a real, scaled cloud-data-protection platform with confirmed historical unicorn status, but stale valuation anchors, thin 2026 disclosure, and AWS/secondary-market concentration keep it in track territory.
Track: Gopuff has genuine category leadership as the last scaled vertically integrated quick-commerce platform in the US and UK, but today's $8.5B private mark already prices in much of the operational recovery while audited financials, free-cash-flow timing, and capital-structure overhang remain opaque.
Tekever is a rare battle-proven European UAS unicorn with credible sovereign demand anchors, but the £1B+ entry price is stretched against unaudited revenue and an undrawn OVERMATCH framework — track until data-room access confirms the financial thesis.
CMR Surgical is a compelling strategic asset — the only globally deployed non-ISRG soft-tissue surgical robot with both CE mark and FDA authorization — but a 2021 vintage $3B valuation, fully opaque financials, and unproven US commercial execution justify a Track recommendation at medium confidence with high risk.
AG1's genuine $600M revenue scale and durable subscription moat are real but insufficient to justify a conviction BUY absent audited financials, resolved FDA inquiry, and NRR disclosure; TRACK with medium confidence and high risk.
Relativity has a differentiated manufacturing-plus-launch thesis and meaningful signed demand, but Terran R is still pre-flight, backlog is not revenue, and opaque post-2021 financing plus brutal launch competition make the equity interesting to track rather than underwrite aggressively today.
Vast Space has achieved real hardware progress with a credible team, first-mover positioning in post-ISS LEO stations, and a $500M institutional round—but the binary dependencies on SpaceX, NASA CLD award, and pre-revenue status at >$2B implied valuation make this a research-more / track situation, not a buy.
CRED has built real premium consumer-fintech scale and improved operating leverage, but under-disclosed credit economics, partner complexity, and a still-stretched $3.5 billion mark make fresh underwriting premature.
Eruditus has the strongest university-partner moat in online executive education and improving fundamentals, but its $3.2B flat-round valuation at 7.1x FY24 revenue — a 3-5x premium to public edtech comps — combined with opaque consolidated financials and undisclosed debt terms make research-more the only defensible call.
GOAT is a real, scaled resale asset, but the public evidence still supports avoidance at the current visible $3.3B-$3.7B range: post-FTC trust risk, thin financial disclosure, and mixed secondary signals leave investors underpaid for opacity.
Miro has real platform scale and strategic relevance, but the public evidence does not justify paying toward the 2022 $17.5B mark without fresh proof on ARR quality, retention, and current price.
Zocdoc has real marketplace scale, a materially improved per-booking model, and credible AI / partner expansion paths, but the underwriting case remains constrained by severe financial opacity, provider-friction risk, and a current valuation signal that is far below its legacy unicorn headline.
Age of Learning has a durable brand and 15 years of product investment in early childhood education, but the $3B 2021 last-round mark is materially stretched relative to current EdTech multiples, undisclosed financials, and subscriber attrition since the COVID peak.
Discord has real consumer-scale proof and a durable community moat, but the $15B entry price outruns the public financial disclosure package.
upGrad is India's most credible edtech investment post-Byju's, but the $2.25B entry mark requires bull-case delivery on FY26 EBITDA.
Tenstorrent is a technically credible AI chip challenger with a differentiated RISC-V architecture and $2B in capital, but unconfirmed revenue, software immaturity, and TSMC sole-source risk warrant a research-more stance at a $3.2B valuation.
Eikon has Nobel-pedigree platform science and a Merck-partnered pivotal trial, but the IPO at ~60% below private valuation and unvalidated core SMT platform demand careful diligence.
Hippocratic AI commands a $3.5B valuation on unverified revenue of an estimated $10–50M ARR, implying 70–350x trailing multiple — stretched even for a high-growth healthcare AI leader. Track pending audited revenue disclosure and observable NRR data from named health system customers.
Zap Energy has moved beyond a slideware fusion story with credible plasma, systems, and DOE-reviewed plant-engineering progress, but the 2026 fusion-plus-fission expansion widens commercialization, licensing, and financing risk before customers, economics, or current price discovery are visible.
Powerful backers and a credible payer pain point are real positives, but Tala's public evidence is too thin to justify its $1.2B entry price today.
Loadsmart has credible platform breadth and improving operating discipline, but limited financial disclosure, freight-cycle sensitivity, and stale unicorn pricing keep the investable call at research-more.
Strive has real kidney-care scale, channel breadth, and product relevance, but the public record still cannot bridge its September 2025 ~$1.8 billion mark to disclosed revenue, margin, renewal, and post-reset economics, so the right public-only posture remains research-more.
Komodo Health has a credible Healthcare Map data asset and 600+ customer footprint, but a stale 2022 Series D mark, severe peer compression, and rising regulatory scrutiny make the $3.3B valuation hard to defend without fresh disclosure.
Neuralink is the flagship invasive BCI platform with credible clinical and financing momentum, but absent public economics, unresolved reimbursement and long-term support dependencies, and a stretched ~$9B-$9.6B valuation anchor keep the name in research-more territory.
Outschool appears to be a real, scaled K-12 live-learning marketplace, but public evidence does not justify underwriting the 2021 $3B mark without private financial and retention data.
Xendit is a credible regional payments infrastructure winner with real scale and product breadth, but opaque current economics, concentration, and regulatory or operational exposure keep the recommendation at research-more and make premium pricing above the unicorn floor look stretched.
Replit has real category-leading adoption and enterprise momentum, but the current $9B mark still outruns the quality of public financial disclosure.
vVardis has created a genuinely novel dental therapeutic category with rapid US institutional adoption and unicorn-level backing, but the complete absence of disclosed financials and persistent insurance reimbursement gaps support only a research-more stance until an S-1 filing provides the evidence needed to underwrite the $1B+ private-market valuation.
Differentiated brokerage infrastructure asset with a credible self-clearing moat and rapid ARR growth, but private opacity on margins, concentration, and the cap table prevents a conviction buy at the $1.15B mark.
Svante holds the world's only solid-sorbent carbon-capture filter gigafactory and the strongest strategic investor syndicate in its category, but is pre-revenue with all commercial projects pre-FID and no disclosed financials, warranting a research-more stance pending FID confirmations and greater disclosure.
LumApps has built a credible AI employee hub at genuine enterprise scale with $150M combined ARR and Bridgepoint sponsorship, but private-company opacity, Beekeeper integration risk, and a stretched >$1B valuation limit confidence to a track stance until NRR and gross margin are disclosed.
Boom Supersonic holds the most credible post-Concorde supersonic aviation position — with 130 aircraft pre-orders, a June 2025 regulatory tailwind from the overland ban repeal, and proven XB-1 aerodynamics — but remains pre-revenue and a decade from commercial service, making this a high-risk speculative position appropriate only for patient strategic capital.
Newcleo has stronger technical depth and regulatory traction than many European advanced-nuclear peers, but the public case still depends on repeated financing, future customer conversion, and milestone execution at a valuation that already prices in meaningful success.
80 Acres Farms appears to be the most credible remaining U.S. vertical-farming consolidator, but no audited financials and no disclosed valuation justify TRACK rather than BUY.
Tomorrow.io has a technically differentiated satellite moat validated by NOAA and institutional investors at unicorn scale, but an unresolved 4× ARR discrepancy, undisclosed gross margin, and capital-intensive DeepSky program make commitment at $1B unjustifiable without data-room confirmation.
Also has authentic Rivian engineering DNA, a differentiated DreamRide propulsion system, and a DoorDash commercial anchor—but it is a pre-revenue hardware startup valued at $1 billion before mass production, with unresolved delivery timelines, battery-safety regulatory exposure, and capital requirements that make the current benchmark high-risk for new investors.
Fuse Energy is a founder-led, vertically integrated UK energy challenger with credible traction and product breadth, but the reported $5 billion valuation is hard to underwrite from public evidence because ARR quality, margins, liquidity, and private-round terms remain opaque.
Veho is a high-growth last-mile delivery operator with genuine brand differentiation and strong customer outcomes, but existential IC reclassification risk, a four-year-stale $1.5B valuation mark, and complete financial opacity cap conviction at "track" pending audited financials and a capital raise event.
Wellhub is the global leader in employer-sponsored wellness benefits with $319M ARR and genuine platform scale, but its $4.2B secondary-market valuation implies a 13.2x EV/ARR multiple on undisclosed financials — stretched versus all public and private comps — warranting a Track stance until gross margin, NRR, and post-USC integration economics are confirmed.
Lyten holds genuinely differentiated Li-S battery chemistry and the acquired manufacturing infrastructure to scale it — but deep commercial opacity, no audited revenue, a stretched $1.3–1.5B estimated valuation relative to peers, and a heavy capital burden from two European facility acquisitions make this a Track at Low confidence until EXIM conversion, binding OEM contracts, or audited financial disclosure reduces uncertainty.
Track Rappi until its IPO S-1 surfaces audited financials; the equity-round valuation ($5.36 B) is stretched at ~4× unverified revenue while secondary markets clear at $1.77–2.0 B, a 66% discount.
Eon's repeat-exit founders, tier-1 investor syndicate, and triple-digit revenue growth are compelling, but its $4B valuation is structurally unverifiable without disclosed ARR — TRACK until a data-room package closes the gap.
xAI has real compute, distribution, and execution advantages at scale, but the $230B valuation cannot be underwritten from public data — research-more until private financials are accessible.
KEENON is the uncontested global leader in commercial service robotics with 70,000+ deployed robots and IDC Triple No.1 rankings, but a four-year funding silence, complete financial opacity, and compounding geopolitical risk constrain conviction to a track/research-more stance at the implied $2B valuation.
Doctolib has real European workflow-platform scale and improving subscription economics, but the current ~€3.6B secondary still looks stretched given opaque margins and capital structure plus a live French antitrust overhang.
Covariant is a technically differentiated AI robotics software company at an inflection point: the $2.7B valuation is hard to justify without the founding team, but the installed base and RFM-1 technology retain real strategic value for acquirers and patient investors.
PsiQuantum has the most credible photonic FTQC thesis and strongest government backing in the sector, but the $7B entry price is wholly speculative on a 2027 milestone that has no independent validation and carries critical timeline and execution risk.
Flock Freight is the only patented STL category creator in a large US freight market, but complete financial opacity and a $1.4B 2021 peak valuation support only a conditional hold above $1.0B EV.
Formation Bio has a compelling AI-pharma thesis backed by $615M in blue-chip capital and top-10 pharma partnerships, but the $1.8B valuation rests on unverifiable AI performance claims, undisclosed financials, and a high-risk drug pipeline where industry-wide failure rates exceed 90%.
Pass-with-watch in 2026: 2024 restructuring overhang, undisclosed retention / concentration metrics and uncertain FortoLabs production scope outweigh the multi-vertical breadth and CSRD/CBAM tailwind; deal-stage trigger on next-round disclosure or accretive financing event.
Altos Labs is a scientifically ambitious but extremely high-risk pre-revenue longevity research platform with a world-class team, a $3B war chest, and no proven path to clinical translation or commercial revenue within the next decade.
MasterClass is a premium EdTech brand with strong content differentiation, but faces a severe valuation gap from its 2021 peak, ongoing financial pressure from layoffs and high content costs, and growing commoditization risk from AI.
Overhaul is a conditional pass — a vertically differentiated, Fortune-100-proven cargo security platform with a credible demand thesis, but financial opacity and sector multiple compression require data-room confirmation before conviction at any entry price above $500M.
Lalamove is Asia's dominant on-demand intra-city logistics network with a credible investment thesis, but its Series F valuation (9.6x EV/Revenue) is unsupported by public comparables; entry at base-case multiples (5–7x, US$5.2–7.3B) requires confirmed IPO progress and resolution of the gig-worker and PIPL regulatory overhangs before a positive view is warranted.
Grammarly has an unmatched distribution moat (30M+ DAU, 96% F500) and genuine AI writing IP, but is overvalued at $13B (~18–20× ARR) with 12% growth; do not enter at current price — TRACK and re-evaluate at $5–7B when post-rebrand KPIs and GC covenant terms are confirmed.
Dream Security has built a technically credible sovereign AI cybersecurity platform with exceptional ARR velocity, but the $1.1B valuation at fewer than ten signed government contracts—combined with unresolvable leadership legal risk and zero public financial disclosure—argues for a conditional 'track' rather than 'buy' until three sovereign references, external legal opinion, and audited financials are confirmed.
Machina Labs has a genuinely differentiated electromagnetic forming technology with real defense traction, but sub-unicorn scale, revenue opacity, and tooling-scope limitations constrain near-term investability.
Character.AI has built a dominant AI companion platform with 45M MAU and a cash fortress from the Google deal, but the teen safety litigation cluster and Google API dependency create a risk profile that is difficult to price at the current $2.7B implied valuation.
Flexport: Credible digital freight platform at a stretched valuation — TRACK until profitability confirmed
Wayve has built the most advanced OEM-licensable AV system in Europe and secured $1.05B in validation from SoftBank, NVIDIA, Microsoft, and Uber — while remaining entirely pre-revenue after eight years of operation. The UK AV Act 2024 creates a genuine regulatory first-mover window, but Wayve's core technical approach (black-box end-to-end neural networks) directly conflicts with regulatory certification requirements that DVSA has not yet formally addressed. TRACK until first OEM commercial agreement or DVSA certification pathway is publicly confirmed. Entry above $5B inadvisable before those milestones.
Thinking Machines Lab has assembled arguably the strongest AI infrastructure team in history, but it is pre-revenue, has lost three of six founding co-founders in Year 1, and is targeting a $50B valuation with no financial evidence to support it. Research-more at current reported price; re-evaluate after first ARR cohort.
Botshare addresses a real adoption pain point in robotics, but the company is too young and too lightly disclosed to justify strong conviction at a unicorn valuation.
Agilink shows unusually strong early commercialization and investor pull for a dexterous-hand startup, but thin disclosure, parent dependence, and a stretched $1B+ valuation justify a research-more stance.
Robot Era has stronger public deployment and financing proof than most humanoid startups, but the current mark still looks investable only with more diligence because commercialization quality and economic disclosure lag the valuation narrative.
HomeLight has built a real multi-product residential transaction platform with meaningful reach and credible customer pain-point fit, but opaque current financials, capital-sensitive product mix, regulatory exposure, and a post-2022 valuation reset keep the recommendation at research-more.
ICON has real technical and deployment proof, but the public record is still too thin to justify paying anywhere near the old ~$2B mark with confidence after layoffs and a much smaller, valuation-undisclosed Series C.
Flash Express is a real Thai logistics scale winner with verified 2024 profitability, but thin margins, opaque private-market terms, and a stale 2022 valuation anchor justify a research-more stance rather than fresh underwriting at the last mark.
Pacific Fusion combines elite scientific talent, unusually transparent technical evidence, and extraordinary early capital, but the public record still lacks the price, structure, and customer proof needed for a responsible underwriting call. Recommendation: research-more until term-sheet, full-module, and counterparties evidence closes the gap.
Kikoff has real customer reach and a differentiated low-friction credit-building bundle, but the public record still leaves too much uncertainty around retention, complaint quality, and revenue to underwrite the reported unicorn valuation with conviction.
Acronis is a credible channel-anchored cyber-protection platform with a fresh EQT capital event at an implied $3.5B EV, but no audited financials and a first-ever FASCSA federal exclusion order make this a research-more, not a conviction, story for 2026 underwriting.
Epic Games owns exceptional gaming and engine assets, but current public evidence supports only a cautious research-more stance because Fortnite concentration, platform dependence, and private-company opacity make the last hard $31.5 billion valuation look expensive.
Hive Box has unmatched domestic smart-locker density and early profit improvement, but unresolved redemption litigation, consent-driven regulatory pressure, and a stale 2024 private mark keep the case in watchlist territory.
Galaxea AI has best-in-class academic credentials, a credible product roadmap, and genuine developer traction, but zero verified commercial revenue, a stretched ~$2.9B valuation implying >290x on 2025 guidance, and high geopolitical and disclosure risk that make it uninvestable without further transparency.
Tenex is a credible AI-native MDR operator with exceptional fundraising momentum and real early customer proof, but the public file is still too thin and too self-reported to justify conviction at a reported valuation above $1B.
Plus.ai has credible L2+ traction and a differentiated camera-first architecture, but the $1.2B SPAC entry price requires L4 commercial proof that does not yet exist.
Etched is a technically credible Transformer-ASIC bet with a compelling throughput thesis, but zero customers, no tape-out confirmation, and existential architecture-shift risk make this a high-conviction speculative position at any valuation above $600M.
Hailo has genuine technology differentiation and a growing edge AI platform, but undisclosed financials, a 4-year funding gap, and an opaque customer base limit conviction at the $1.13B last-known valuation.
Colossal's de-extinction narrative is genuine and its team is world-class, but a $10.3B entry price implies 1,000x trailing revenue with no near-term de-risking catalyst — the math only works in a narrow bull case.
Climeworks leads commercial DAC but its flagship plant is producing 0.3% of capacity—a binary operational risk that dominates the investment case until resolved.
CAUTION — World-Class Team, Extreme Valuation; Watch for Commercial Proof Before Entry
Substrate is pursuing a bold and strategically relevant U.S. lithography-and-foundry thesis, but the current public record still supports only a medium-confidence research-more stance: the company has fundraising momentum and intriguing technical signals, yet lacks customer, throughput, yield, and financing proof commensurate with its roughly $1 billion valuation.
A first-of-its-kind commercial plasma-pyrolysis producer with real technology and blue-chip backing, but thin public financials, single-plant scale, customer/loan concentration and a DOE loan under cancellation threat warrant deeper diligence before underwriting the $1B+ valuation.
Deepwatch has credible AI-native MDR product-market fit and enterprise customer proof, but pervasive financial opacity, three CEOs in under two years, and workforce reductions that targeted core MDR delivery staff make this a high-risk tracking position rather than an actionable buy until financial and leadership clarity improves.
Devo has genuine cloud-native SIEM differentiation and strong NRR, but the $2 billion valuation at ~28x ARR is materially unsupported by current market comps — a constructive investment stance requires price discovery, an updated ARR milestone, or Gartner MQ re-inclusion before the risk-reward is favorable.
Orca Security is the agentless CNAPP pioneer under existential competitive pressure from Wiz; its $1.8B Series C mark is at severe risk of markdown given Wiz's 3x estimated ARR lead, active IP litigation, and a financing environment that has penalised cybersecurity late-stage rounds since 2022.
Retro has credible science, elite backers, and a real first-in-human milestone, but public evidence still supports a research-more stance because the $1.8 billion pre-money mark is ahead of disclosed efficacy, economics, and commercial proof.
Story Protocol has credible technical differentiation and real AI/IP narrative tailwinds, but public evidence still supports only a research-more stance because revenue, enterprise adoption, and legal enforceability remain unproven while valuation looks stretched versus token-market and usage signals.
Sidecar Health has a differentiated transparent-plan model and real strategic validation from Koch, but the company still withholds the underwriting, scale, and cap-table data needed to price the risk with conviction.
Xpanceo has assembled rare capital and a credible prototype engine around a potentially important post-screen interface, but the company is still years from a publicly validated commercial product and the last disclosed valuation already prices in milestones that remain unproven.
Statsig built a credible integrated experimentation platform, but the announced OpenAI deal and still-private economics make it an avoid for fresh capital.
Aiven has credible product breadth, enterprise customer proof, and multi-cloud differentiation, but the stale $3B 2022 mark is not investable in 2026 given opaque financials, heavy competitive pressure, and uncertain capital adequacy.
Rebellions has the strongest strategic positioning of any Korean AI chip startup, but the current $2.34B price is supported far more by sovereign-AI optionality and investor backing than by publicly disclosed commercial scale.
Genki Robotics combines elite founder pedigree and strong Japan robotics tailwinds, but the current $1 billion Series A price materially outruns public proof on product, customers, and economics.
GI WaaS has credible wastewater-treatment activity and Saudi market tailwinds, but the reported unicorn valuation outruns the quality of its public disclosure.
Skyroot has real technical progress, capital backing, and manufacturing ambition, but the orbital launch, customer, and unit-economics proof still trails the current $1.1B valuation.
GoodLeap is a scaled category survivor, but the stale $12B private mark, ABS stress, live consumer-finance litigation, and limited private disclosure make the right action track / research-more rather than buy near the historical valuation.
TAE has one of the stronger publicly visible private-fusion science programs, but today's entry price is unsupported by disclosed plant economics, customer proof, or the pending merger's full disclosure pack.
Ninja Van has real regional logistics scale and credible adjacencies in B2B restocking and cold chain, but weak public financial disclosure and a 2025 valuation reset leave the current underwriting case incomplete.
EvolutionaryScale produced frontier-quality protein language models (Science-validated ESM3) but the November 2025 CZI absorption — barely 14 months after the $142M Series A — eliminates the standalone investment thesis and leaves commercial investor returns publicly unaccounted for.
Unconventional AI is attacking a real and increasingly important AI power bottleneck with rare founder-market fit and exceptional access to capital, but public evidence still supports treating it as a thesis-driven research bet rather than an investable operating company at the current price.
Noom is a real, large-scale consumer-health brand whose 2021 $3.7B mark is no longer credible — secondary markets already imply ~$720M — and whose investability now hinges on whether the GLP-1 Noom Med pivot can offset behavioral-app revenue decline and structural disruption.
SSI is a high-conviction, pre-revenue AI safety bet priced at $30B on founder optionality alone — not current business fundamentals.
Sanctuary AI has top-tier humanoid-robotics IP and credible strategic backers, but the absence of disclosed customers, revenue, or valuation — combined with the November 2024 co-founder departure and contradictory financing reports — makes underwriting premature.
Brex's $5.15B Capital One outcome (April 2026) crystallises a 58% discount to the 2022 peak: a workable enterprise-fintech exit but a decisive failure of the standalone unicorn thesis — TRACK / AVOID at pre-acquisition private secondaries; the deal is now a Capital One integration story.
Hark has elite founder pedigree, capital, and compute access, but the public record still supports an avoid stance because a $6 billion Series A valuation is ahead of disclosed customer, product, and economic proof.
EnergyX holds genuine DLE technology optionality and strategic-investor validation, but a $3.26 billion management-set implied valuation unsupported by commercial revenue, independent appraisal, or institutional follow-on keeps the stance at TRACK with LOW confidence and HIGH risk.
Promising process IP never matured into a diversified base of gigawatt customers before partner concentration, capital intensity, and a battery-market downturn pushed 24M into liquidation.
Turntide has a differentiated technology platform but zero public financial evidence, zero named customers and a stale $2.8B valuation make it uninvestable from public sources alone.
Advance Intelligence Group is one of the most advanced SEA fintech multi-product platforms at profitability inflection, but undisclosed credit quality and an uncertain IPO path make this a conditional accumulate at or below the 2021 round valuation.
Ascend Elements has real battery-material technology and customer interest, but its April 2026 Chapter 11 filing turns the case into a distressed-asset situation rather than a normal late-stage growth investment.
Natron Energy is a post-shutdown liquidation legacy file with real technology and manufacturing proof, but no live underwriting case and no publicly verified unicorn valuation.